2017 Annual Report
Leading the Way to Cancer Cures
President & Chairman’s Message

Thanks to your support, 2017 was a tremendous year for The Leukemia & Lymphoma Society’s lifesaving mission and the patients and families we serve. You help fund research to find the next breakthrough therapy, you provide information and support to patients, and you make sure patients have access to lifesaving treatments.

Extraordinary progress is bringing us closer to cures. You make that possible.

Gratefully,

Louis J. DeGennaro, Ph.D.
President & Chief Executive Officer

Peter Brock
Chairman of the Board

Table of Contents

PRESIDENT & CHAIRMAN’S MESSAGE .......................... 2
VOLUNTEERS ................................................. 3
RESEARCH ...................................................... 6
PATIENT EDUCATION & SUPPORT .......................... 11
POLICY & ADVOCACY ....................................... 15
FUNDRAISING CAMPAIGNS .................................. 19
PARTNERSHIPS .................................................. 23
FINANCIALS ..................................................... 24
ACKNOWLEDGMENTS ......................................... 41

Our Mission

At LLS, our mission is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Compared to any other blood cancer nonprofit, LLS is the largest funder of cutting-edge research to advance cures.

Dr. Gwen Nichols
Chief Medical Officer, LLS
This year, LLS volunteers made a significant impact while selflessly dedicating their time and talent to achieve our mission. With countless ways to engage, from fundraising to providing patient support, our volunteers are changing the landscape of cancer.
Campaign Volunteers

With five signature fundraising campaigns, our volunteers can run, hike, walk, sail, build teams and gain lifelong learning skills while raising funds to drive forward our mission to end blood cancers.

MORE THAN 650,000
Team In Training teammates ran, hiked, cycled and climbed while raising funds since it began 30 years ago.

One million friends, families and co-workers gather together carrying illuminated lanterns in 150 inspirational Light The Night evening events, helping bring light to the darkness of cancer.

MORE THAN 27,000 schools participate in Student Series, a set of science-based philanthropy programs run by volunteers helping to fight blood cancer.

900 candidates across the country competed to win the title of Man & Woman of the Year by raising funds in honor of local blood cancer survivors.

MORE THAN 400 motivated high school students across the country joined Students of the Year in its inaugural year.

MORE THAN 11,000 sailors, friends and sponsors set sail to raise money to cure cancer at Leukemia Cup Regatta events since it began 30 years ago.

Mission Volunteers

In communities across the country, volunteers provide support directly to blood cancer patients and caregivers, and advocate for legislation to improve access to care.

MORE THAN 100,000 volunteer advocates are effecting change by advocating for policy at the state and federal level.

NEARLY 8,000 volunteers across the nation provide direct support to patients and families in their communities.
Leadership Volunteers

We have the unwavering support of hundreds of top leaders across the country, helping us fulfill our mission to find cancer cures.

26 leaders serve on our National Board of Directors, providing leadership and governance to help find blood cancer cures.

MORE THAN 800 leaders serve on Boards of Trustees for our local chapters providing thought leadership and fundraising support.

16 of the best scientific and medical minds serve on our Medical Scientific Affairs Committee to review grant applications and select the most promising research for funding.

21 professional volunteer clinical advisors review materials to ensure the blood cancer information we share is accurate and up-to-date.

Community Volunteers

With 56 chapters across the country, there are many opportunities for volunteers to lend their time and talent in their own community, as well as in our national office.

Countless volunteers helped prepare, staff and support our chapters and national office leading up to and on the day of events.

Numerous skill-based volunteers lend their talent with anything from administrative responsibilities, high-level projects to raising awareness.
As there are no means of preventing blood cancers, the LLS research agenda is focused on finding treatments and cures. In fact, we have invested more than $1.2 billion in research since our inception 68 years ago. For every victory in blood cancer, challenges remain. That is why LLS remains steadfast in our commitment to advance the most promising research around the world and drive forward innovative therapies that improve and save the lives of patients.
Since 1949, LLS has supported the work of remarkable scientists leading to breakthrough advances in blood cancer treatments. To date, **LLS has invested more than $1.2 billion in cutting-edge blood cancer research**, funding nearly all of today’s most promising treatments, and bringing us closer to cures.

This year, LLS dedicated $42 million to support scientific grants, including 83 new grants awarded in 2017 alone to researchers across 8 countries, making us the largest nonprofit funder of blood cancer research. Most of these grants are supporting research projects over multiple years. LLS supports the full spectrum of research from bench to bedside – that is, from basic, laboratory-based research to large-scale clinical trials. In 2017, we supported a total of 227 research grants, a $211 million multi-year commitment.

Through our Therapy Acceleration Program® (TAP), we partner directly with biotechnology companies and renowned academic centers to help accelerate the development of promising therapies. This year, $4.7 million of our 2017 research budget was invested in our TAP program. TAP is currently supporting 19 partnerships.

Through these investments, we accelerate science in order to improve the lives of those impacted by blood cancers. While significant progress has been made, much work remains. There is an urgent need for new treatments and every hour spent conducting research is a step closer to finding cures.

**VOLUNTEER SPOTLIGHT: SANDY ALLEN-BARD**

Fighting blood cancer is a cause that has always been close to my heart. I lost my grandfather to acute myeloid leukemia in 1971. Today, I work as a nurse practitioner focused on leukemia at the Weill Cornell Medical College/New York Presbyterian Hospital.

Since 2003, I have volunteered for LLS in many ways. I first signed up for Team In Training (TNT) in support of the patients I treat. I am now a TNT coach and I’ve completed 30 marathons and three 50-mile races. My greatest accomplishment is raising more than $260,000 over multiple campaigns, which funded research at Weill Cornell Medical College and research dedicated to AML.

I’ve also volunteered for LLS’s patient outreach efforts. I started a patient support group at Weill Cornell Medical College, and I have given many lecture series. I was active in the LLS Community Service Committee programs, and I was team captain for Light The Night. I will continue to volunteer for LLS until we find a cure.
Our sustained research investment is helping save and improve the lives of patients. This year the U.S. Food and Drug Administration (FDA) approved 18 treatment options for patients who urgently need them. What’s more, LLS played a role in virtually all of these advancements.

A Breakthrough in Cancer: CAR T-Cell Immunotherapy

This year we witnessed a historic victory for cancer patients when a revolutionary, innovative immunotherapy was approved, ushering in a new era in the treatment of cancer and other serious and life-threatening diseases.

The FDA approved the first CAR T-cell immunotherapy, a treatment in which a patient’s T-cells, the soldiers of the immune system, are genetically reprogrammed to find and kill cancer cells. LLS recognized the early promise of this approach. Over the past two decades, LLS provided $40 million in funding for more than 15 researchers and companies around the world to develop this revolutionary approach to treating cancer.

LLS’s long term investment paid off when two CAR T-cell immunotherapies were approved by the FDA this year:

- **Tisagenlecleucel (Kymriah®)** was the first CAR T-cell immunotherapy approved for children and young adults up to 25 years of age who relapsed or did not respond to therapy for acute lymphoblastic leukemia (ALL).
- **Axicabtagene ciloleucel (Yescarta®)** was approved for adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.

This is an extremely promising development for patients who have otherwise run out of treatment options. It has also dramatically stimulated research and clinical development exploring the use of CAR-T for solid tumors.
KIM SCHUETZ

My work with LLS began when I was an oncology nurse, and our inpatient unit put together a team for Light The Night (LTN). It was a great way to support my patients and get involved in our new community after moving.

Then, in 2011, the unthinkable happened. My two-year-old son, Austin, was diagnosed with leukemia. It hit us like a ton of bricks. I had been taking care of others with cancer, but never imagined that I’d have to do the same for my son. My mission became to educate others about blood cancers and to raise funds.

Because of breakthrough research funded by LLS, my son is here today. After we ran out of treatment options when he was five years old, we enrolled him in a clinical trial for CAR T-cell immunotherapy. A therapy LLS has funded for two decades. Today, he is cancer free.

Our family volunteers with LLS in many ways – we started Team Austin’s Courage for LTN and I participated in Man & Woman of the Year (MWOY). During my 2014 MWOY campaign, I was able to raise the most funds in 10 weeks while we were traveling back and forth to Philadelphia here Austin was being treated. Winning Woman of the Year was one of my greatest moments, and I’m proud that I could do this in honor of Austin.

JOHN KELLEY

A tribute by his daughter, Cristina Kellenyi

My dad, one of LLS’s most dedicated volunteers, lost his battle to cancer this July. My dad ran a total of 40 marathons in his lifetime. In 1999, he began volunteering for LLS and ran several Team In Training marathons and half marathons. He even learned to swim in order to participate in his first Ironman.

His physical efforts were matched by his fundraising efforts. Prior to becoming so passionately committed to LLS, he was a successful hedge fund manager and research analyst on Wall Street. He applied much of the same acumen he used during his career in finance to his involvement with the local New Jersey chapter. He served as chapter president and as a long-time board member.

My dad also served as National Vice-Chairman for LLS’s Beat AML Master Clinical Trial. In addition to his huge efforts for Beat AML toward the end of his life, my father was also heavily involved in fundraising for the first significant advance in AML treatment in 40 years, in addition to many other contributions.

My dad was highly recognized by LLS, receiving the prestigious Spiral of Life award in his final days. He continues to inspire so many people by his determination, heartfelt energy, humility, generosity, selflessness, and hard fought achievements. My dad is greatly missed by LLS and the family that he loves so much.
LLS is leading the offensive against acute myeloid leukemia, one of the most deadly blood cancers that has seen little change in the standard of care in 40 years and impacts 21,000 Americans annually. LLS is taking a multi-faceted approach with a paradigm-shifting clinical trial as its centerpiece. The Beat AML® Master Clinical Trial builds upon an earlier genetic study commenced in 2013 to better understand the underlying drivers of the disease.

In October 2016, LLS launched an innovative precision medicine Beat AML® Master Clinical Trial to test targeted therapies for acute myeloid leukemia (AML). The unprecedented collaboration includes multiple leading cancer centers and pharmaceutical companies, a clinical research organization, and a genomics analysis company. The protocol for the trial was developed with input from the FDA, which is eager to see new models for cancer clinical trials.

AML is extremely complicated to treat because it is not a single disease, but a group of more than 10 different major subtypes and other rare mutations. With advances in genomics, we can now identify and target specific types of AML. This precision medicine approach is the key to new therapies for patients.

The trial employs advanced genomic technology to identify each patient’s individual cancer-driving genetic mutations, and then matches that patient to the most promising, targeted treatment.

“It’s the ultimate precision medicine – matching a specific targeted therapy to the specifics of a person’s individual leukemia,” says one of the trial’s co-lead investigators, Ross Levine, MD, of Memorial Sloan Kettering Cancer Center.

LLS is the first nonprofit health organization to sponsor a cancer clinical trial. To date, LLS’s trial has exceeded all milestones.
As the leading source of free blood cancer information, education and support for patients, survivors, families and healthcare professionals, LLS helps patients navigate their cancer treatments and ensures they have access to quality, affordable and coordinated care. Research will help us achieve an end to blood cancers. In the meantime, patients need help before, during and after their diagnosis and treatment. LLS is the leading nonprofit that does just that.
Research will help us achieve an end to blood cancers. In the meantime, patients need help before, during and after their diagnosis and treatment. LLS is the leading nonprofit that does just that.

As the leading source of free blood cancer information, education and support for patients, survivors, families and healthcare professionals, LLS helps patients navigate their cancer treatments and ensures they have access to quality, affordable and coordinated care. In 2017, we:

- **Responded to nearly 18,000 inquiries** to LLS’s Information Specialists from people seeking support, information, and resources.
- **Provided $72.97 million in co-pay financial assistance** supporting 31,026 patients.
- **Provided 339 patients with in-depth clinical trial navigation and support** through LLS’s Clinical Trial Support Center.
- **Distributed more than 700,000 educational booklets and fact sheets** about specific diseases.
- **Educated 10,000 patients, caregivers, health care professionals and others** through live web-based and local in-person programs.
- **Reached nearly 6,000 patients and caregivers through LLS Community**, an online social network that provides education and support.
- **Developed an innovative partnership with Walgreens** to enhance support to blood cancer patients and implement a novel pharmacist education and training program.

**Reaching patients in their communities**

As a community-based voluntary health organization, we have regional and local chapters throughout the United States and Canada so that we can support blood cancer patients in every community. This year through our community-based programs we:

- **Connected 1,100 volunteers with patients and caregivers** diagnosed with the same disease through LLS’s Patti Robinson Kaufmann First Connection Program.
- **Facilitated 135 support groups** in local communities led by nurses and social workers.
- **Convened 10 regional Blood Cancer Conferences** with nearly 3,500 patients in attendance.
GARY THOMPSON

A six-year-old boy named Kethan, who was battling acute lymphoblastic leukemia while my wife battled breast cancer, changed me forever. In 2008, I had been named the first Man of the Year in Austin, Texas. But, my wife and Kethan inspired me to do more. I dusted off my bike and did my first Team in Training ride around Lake Tahoe in 2010.

I participated in that ride for seven more years – only three of which Kethan was alive for. He passed away in summer of 2013, and my wife passed away in fall of 2014. Until my last breath, I promised would do everything I could to fight cancer.

From chairing the Board of Trustees in Austin, serving as a member of the National Board, and chairing LLS’s inaugural corporate partnership council, I have been privileged to raise funds and awareness for LLS.

My proudest moment was when LLS and Walgreens announced their collaboration to provide patients and their caregivers with access to up-to-date information to best manage their disease. After making an introduction to Walgreens’ then CEO, I worked with my staff partner at LLS for almost two years to bring this collaboration to life.

Through my work with LLS, I have been able to raise awareness and funds, and change the lives of patients. LLS has empowered me to magnify my voice in the fight against cancer.

NANCY H. LAMANNO

In June 2015, I lost my husband Barry to acute myeloid leukemia. He had battled the disease for 18 months, including undergoing a stem cell transplant. When he was diagnosed in December of 2013, the first thing I did was to search online for AML and I found the LLS website and read every word available.

Despite facing a deadly disease and eventually losing the battle, the support we received throughout my husband’s treatment made it a surprisingly positive experience. I sold my business during this time and once my full-time job as a caregiver was over, I wanted to take all that knowledge that I had gained and use it for good.

Three times a week I speak with patients and their families about LLS and the wonderful programs and educational information available to them as a Patient and Family Outreach Coordinator for the Georgia Chapter. Families facing a blood cancer diagnosis love to hear that LLS offers financial and emotional support as well as information and education.

I have also become a First Connection volunteer coordinator, joined LLS’s advocacy efforts, and volunteer at local events. I receive a far greater benefit by volunteering with LLS than I give – I have a sense of purpose and fulfillment that I have never before experienced.
Celebrating 20 years of helping patients

The year 2017 marked 20 years of LLS’s Information Specialists providing personalized support, information and resources to patients and caregivers. Last year Information Specialists answered nearly 18,000 inquiries, providing one-on-one assistance to address patients’ and caregivers’ specific needs.

Information Specialists are oncology social workers, nurses and health educators who have specialized training in the blood cancers. They spend hours speaking with those impacted by blood cancer about their disease, clinical trials, and financial resources, and guide them to LLS’s comprehensive support and educational services. They can be reached at (800) 955-4572 or online at www.LLS.org.

Expansion of Clinical Trial Support Center

This year LLS doubled the capacity of its Clinical Trial Support Center (CTSC), in which specially trained nurses help patients find and enroll in clinical trials based on highly detailed, individualized assessments. The nurses work one-on-one with patients and caregivers to uncover all the important details needed to identify and enroll patients in appropriate trials, from their medical history to their current financial situation. From this information, they conduct a search and provide the patient with a list of trials to take to their physician.

Since it frequently takes time to find an appropriate clinical trial for patients, the CTSC nurses often maintain a relationship with patients and their family for many months and continue to provide support along the way. The majority of patients working with the CTSC have enrolled in one or more clinical trials.

Increasing Myeloma Awareness In African-American Communities

African Americans have twice the incidence of multiple myeloma as white Americans. Recent studies show that African Americans are significantly less likely to receive the newest treatments and combination therapies and more likely to experience treatment delays, including transplant delays.

LLS, with support from The National Black Church Initiative (NBCI), is leading a pilot program to improve access to novel therapies and quality of life among African Americans with myeloma. This program, called Myeloma Link, will provide tools and resources to navigate the treatment landscape more effectively and cope with the disease.

The 18-month pilot program is being carried out in Washington, D.C., and Atlanta, GA. LLS will take learnings from this pilot to expand the program nationally in rural, suburban, and urban areas throughout the country.

Connecting Patients Online

Patients and caregivers told LLS that they wanted to connect with and learn from other patients and caregivers with a similar diagnosis. The solution, LLS Community, is now a place where users go online to share advice, experiences and opinions.

LLS Community is a free online social network that provides support and education to blood cancer patients and their caregivers. It was launched in 2016 and has proved to be a valuable resource for patients and caregivers, growing to nearly 6,000 registered users with over 15,000 user posts in its inaugural year.
Policy & Advocacy

Through our nationwide grassroots network of more than 100,000 volunteers, we advocate for policies at the state and federal level in a commitment to remove barriers to care for blood cancer patients. This year our efforts have helped increase federal research funds, speed the review and approval process of new therapies, and ensure patients are able to access lifesaving treatments.
State Legislative Victories

This year, LLS helped advance laws in Pennsylvania, Alaska and Arkansas to ensure that health plans provide fair coverage of cancer treatments that are administered in pill form. This brings the total enacted “oral parity” laws to 43 states and Washington, D.C. Next year, LLS will continue the push to secure similar laws in Idaho, Michigan, North Carolina, and Tennessee.

Enacted Oral Parity Laws

<table>
<thead>
<tr>
<th>Parity Law Enacted</th>
<th>No Parity Law</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alaska</td>
<td></td>
</tr>
<tr>
<td>Hawaii</td>
<td></td>
</tr>
<tr>
<td>California</td>
<td></td>
</tr>
<tr>
<td>Nevada</td>
<td></td>
</tr>
<tr>
<td>Utah</td>
<td></td>
</tr>
<tr>
<td>Colorado</td>
<td></td>
</tr>
<tr>
<td>Nebraska</td>
<td></td>
</tr>
<tr>
<td>Kansas</td>
<td></td>
</tr>
<tr>
<td>Missouri</td>
<td></td>
</tr>
<tr>
<td>Iowa</td>
<td></td>
</tr>
<tr>
<td>Illinois</td>
<td></td>
</tr>
<tr>
<td>Indiana</td>
<td></td>
</tr>
<tr>
<td>Ohio</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>Maine</td>
<td></td>
</tr>
<tr>
<td>Rhode Island</td>
<td></td>
</tr>
<tr>
<td>Connecticut</td>
<td></td>
</tr>
<tr>
<td>Massachusetts</td>
<td></td>
</tr>
<tr>
<td>Rhode Island</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>Missouri</td>
<td></td>
</tr>
<tr>
<td>Illinois</td>
<td></td>
</tr>
<tr>
<td>Indiana</td>
<td></td>
</tr>
<tr>
<td>Ohio</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td></td>
</tr>
</tbody>
</table>
KATHY HAWKINS

In January 2008, when I was a young, healthy mom of two young boys, I went to a doctor's appointment for fatigue and a pain in my stomach. The next day, I was diagnosed with chronic myeloid leukemia.

My doctor prescribed a new, lifesaving oral treatment, but the out-of-pocket cost was astronomical. Unlike intravenous chemotherapy that is administered in a doctor's office and included under medical coverage, oral cancer treatments are covered through pharmaceutical benefits. Rather than spending a monthly fixed co-pay of about $30, I had to pay a portion of the total drug cost. In my case, this was $2,000 per month.

I was unable to afford this crucial medicine, and I knew I was not alone. I wanted to give a voice to cancer patients in Pennsylvania and beyond. I teamed up with LLS on a seven-year effort to advocate for oral parity legislation. I attended legislative meetings and lobby days, spoke with media and reached out to legislators.

On July 8, 2016, Pennsylvania enacted oral parity legislation into law, thanks to the efforts of LLS, its advocates and patients. My involvement with LLS has only deepened since then. This year, I participated in Man & Woman of the Year, and raised $54,000. I'm proud to continue sharing my story with others, both through my advocacy work at the state and federal levels, and at LLS chapter campaign events. I will continue to advocate for LLS until we find a cure.

AMANDA STEFFY

During my last semester of college, I was diagnosed with chronic myeloid leukemia. Just as I was preparing for track and field season, my world was completely shaken. I did a lot of research to cope with my diagnosis. I learned about LLS and how its research funding was vital to the development of my treatment, imatinib (Gleevec), a revolutionary, targeted cancer therapy.

Within a few months after my treatment, I was able to start running again. I returned to training for my final track season and qualified to run the Boston Marathon. I wanted to give back to LLS because it had given me so much. I would not be here today without LLS-funded research. I decided to get involved with Team in Training (TNT). I started as a participant, then became a mentor and worked my way up to assistant coach. My first season with TNT was incredibly healing. My diagnosis had felt frightening and isolating, but being around such positive people inspired me to share my own story.

After TNT, I participated in Man & Woman of the Year and funded a grant for CML research. I've continued to be involved in the leadership committee and joined LLS's advocacy efforts. I've been proud to meet with elected officials in Washington D.C. the past two years, and I've continued to work with the congressional representative in my home district. This past year, I served as the California Advocacy Committee captain, and remained a First Connection peer for young adults newly diagnosed with CML.

Volunteering with LLS has helped me come to terms with my diagnosis and feel comfortable opening up about my experiences in the hopes of helping others.
Federal Healthcare Advocacy

As Congress debated changes to federal healthcare, LLS advocated that proposed federal healthcare legislation should provide access to stable, quality, affordable coverage to the thousands of blood cancer patients impacted.

- 25,000+ advocate letters
- 2,000+ calls
- 300+ in-person Congressional meetings
- 8 formal letters and public statements

21st Century Cures Act

LLS helped pass the 21st Century Cures Act into law, ensuring reform that will enable the FDA to speed the review and approval of new therapies. This bipartisan bill committed nearly $5 billion in additional funding for the National Institute of Health over the next 10 years, funding that is critical to sustain the current momentum to advance our understanding of the treatment of cancer, including blood cancers.

- More than 30,000 letters were sent to members of Congress
- 100’s of calls were made to house leaders
- 13,000 letters contributed to the passage of the 21st Century Cures Act

Cost of Cancer Care

The rising cost of care for blood cancer patients has reached a boiling point, with an increasing number of patients foregoing their medications or reducing the dosage or frequency of their doctor-prescribed treatments solely for cost reasons. While the cost of drugs makes headlines almost daily, and accounts for 10 percent of health expenditures by patients according to the Centers for Medicare & Medicaid Services, it is just one element of cancer care that causes stress and impeding access to treatment.

In May 2017, in an effort to call attention to this issue, LLS announced a new public position statement on the cost of care and published a range of policy proposals intended to meaningfully reduce costs and mitigate the financial distress facing many patients with cancer. LLS called on every player in the healthcare system – from patient organizations and drug manufacturers, to insurers and pharmacy benefit managers, healthcare providers, hospitals, state and federal governments, and patients themselves – to embrace reforms that promise relief for patients suffering from financial distress.

Learn more at www.lls.org/cancercost.
Thousands of volunteers provided their time and talent in 2017 to make our signature fundraising campaigns a success. Through our campaigns, participants help us support lifesaving research, patient support and education, and advocacy efforts that benefit blood cancer patients.
Thousands of volunteers provided their time and talent in 2017 to make our signature fundraising campaigns a success. Through our campaigns, participants help us support lifesaving research, patient support and education, and advocacy efforts that benefit blood cancer patients. LLS has been a pioneer in creating theme-driven fundraising campaigns, including:

**Light The Night** is a powerful campaign bringing light to the darkness of cancer. One million friends, families and co-workers gather together, carrying illuminated lanterns in 150 inspirational evening walks to celebrate, honor or remember those touched by cancer.

Light The Night had a record year, raising $68.5 million; the campaign has raised more than $625 million since 1999. LTN increased its revenue by 12 percent and was honored as the Peer-to-Peer Professional Forum’s Program of the Year. LTN was named the ninth largest peer-to-peer fundraising program in America and registered the largest dollar increase of any program.

This year, Light The Night introduced Random Acts of Light, engaging celebrities and local heroes to surprise people touched by blood cancers with special meetings, to help brighten their lives during a dark time.

**Team In Training** continues to be the leading charity program that inspires and supports “teammates” with a unique opportunity to experience personal achievement through the Team that provides camaraderie, experienced coaching and fundraising support, and personal discovery.

Team In Training has raised more than $1.5 billion over the past 29 years, training more than 650,000 teammates. As it approaches its 30th year, Team In Training and LLS continue to innovate a platform for fundraisers to change lives, both theirs and those impacted by our mission. Our fundraising opportunities have expanded to include high-caliber events in cycling and climbing. We have had numerous fundraisers summit Mount Kilimanjaro, have upcoming trips to Everest Basecamp and opportunities to cycle over some of Europe’s historic mountains. LLS is supporting the most pioneering cancer research of our time, and you will find a Team In Training teammate moving to support the mission.
Roshan Marksmen

In 2011, I was introduced to Team In Training (TNT) through a friend who had just completed the New York City Triathlon with TNT and wanted me to share the great experience. When I joined, I did not have a direct connection to the cause but over the more than six years of my involvement I have met many teammates, friends, supporters and donors who are impacted by blood cancer. This has motivated me to do as much as I can.

I’ve been involved with LLS in many ways. I have completed 14 fundraising seasons with TNT and my role has evolved from participant, to mentor to team captain. My greatest achievement came last year, when I had the honor of participating in LLS’s Man & Woman of the Year campaign as the first-ever representative from Brooklyn, New York. My other proudest achievements: completing my first half-marathon, climbing to the top of Mount Kilimanjaro in Africa with Climb2Cure, and learning to swim in order to complete my first-ever triathlon.

With all my involvement with LLS I have raised more than $100,000 and I proudly and patiently wait for the day when I can say that I helped contribute to an organization that has developed cures and treatments to help every patient impacted by blood cancer.
Student Series is a service learning, character education, and philanthropy program where students gain the unique experience of helping thousands of people in their fight against blood cancers.

Programs are tailored to each school level so students can grow with Student Series and have an even greater impact on the lives of patients each year. More than 13 million students and 850,000 educators in 27,000 schools across the United States participate annually. Since it began, students have raised more than $315 million to fund breakthrough therapies and patient services, with more than $26 million in this year alone.

Man & Woman of the Year is a truly unique fundraising campaign. In an annual competition in communities across the country, candidates compete in honor of children who are local blood cancer survivors, the Boy & Girl of the Year, by raising funds for LLS.

By engaging influential community leaders, Man & Woman of the Year taps into the spirit of innovation and entrepreneurship that has allowed LLS to achieve great success in funding groundbreaking research to advance cancer cures. The winners receive LLS’s “Man & Woman of the Year” titles. Every dollar raised counts as one vote and the titles are awarded to the man and woman with the most votes at the end of 10 weeks. Top local fundraisers become eligible to win national titles. In 2017, candidates raised $40 million.

One of the premier fundraising programs within the Student Series is the Students of the Year campaign — a campaign that mobilized more than 400 motivated high school students across the country to raise an astounding $6 million in its inaugural year. Ella Behnke is a 16-year-old from San Antonio, TX who earned the winning title, “National Student of the Year,” raising more than $334,768 for cancer cures!

Leukemia Cup Regatta is a thrilling series of sailing events that combines the joy of boating with the important task of raising money to cure cancer. At events held at yacht clubs across North America, skippers register their boats and recruit friends and colleagues to help crew and raise funds. Crew members seek donations from friends, family, co-workers and employers to sponsor their boat.

More than $62 million has been raised through the Leukemia Cup Regatta series for lifesaving research and patient services since its start 30 years ago.

Volunteer Spotlight: Maria Avila

Our son Enrique was only two years old when he was diagnosed with acute myeloid leukemia (AML). Our life changed in a matter of minutes. At the age of three, Enrique received a bone marrow transplant and today, he is a healthy 17 year old.

Soon after his diagnosis, we received an educational resource from LLS, which provided information we needed and gave us hope. Our family wanted to be part of an organization that brought hope and information to families while funding research for cures. We joined Light The Night and formed “Team Familia Avila & Amigos” to raise funds and walk with hundreds of other survivors, caregivers and supporters.

We are so proud to work with LLS to bring light to the darkness of cancer, in honor of our son and the many other families impacted by blood cancers.
Partnerships

We are grateful to our partners and sponsors, who harness the power of their consumers, communities and employees to help fight blood cancers.

For a full list of partners, go to www.lls.org/partners.
We’ve always believed the most efficient way to finding cures for blood cancer is by directing as much funding as possible to the best and most innovative research, while providing patient support and education, and tirelessly advocating on behalf of patients. Your support is invested wisely.
Independent Auditors’ Report

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2017, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2017, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Report on Summarized Comparative Information
We have previously audited LLS’s consolidated financial statements, and we expressed an unmodified opinion on those audited consolidated financial statements in our report dated November 2, 2016. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2016 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

October 27, 2017

KPMG LLP
## Consolidated Balance Sheet

The Leukemia & Lymphoma Society, Inc. / June 30, 2017 (with comparative amounts at June 30, 2016) (In thousands)

### Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$41,401</td>
<td>18,596</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>3,613</td>
<td>2,906</td>
</tr>
<tr>
<td>Contribution and other receivables, net (note 5)</td>
<td>17,785</td>
<td>17,244</td>
</tr>
<tr>
<td>Investments (note 3)</td>
<td>209,421</td>
<td>168,293</td>
</tr>
<tr>
<td>Fixed assets, net (note 8)</td>
<td>10,119</td>
<td>16,946</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$282,339</strong></td>
<td><strong>223,985</strong></td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

#### Liabilities:

<table>
<thead>
<tr>
<th>Description</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$21,711</td>
<td>13,655</td>
</tr>
<tr>
<td>Deferred revenue (note 6)</td>
<td>14,028</td>
<td>12,931</td>
</tr>
<tr>
<td>Awards and grants payable (note 2)</td>
<td>64,052</td>
<td>60,451</td>
</tr>
<tr>
<td>Co-Pay assistance payable (note 2)</td>
<td>20,071</td>
<td>13,469</td>
</tr>
<tr>
<td>Other long-term liabilities (note 9)</td>
<td>3,167</td>
<td>1,638</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>123,029</strong></td>
<td><strong>102,129</strong></td>
</tr>
</tbody>
</table>

#### Commitments and contingencies (notes 2 and 10)

#### Net assets (note 4):

<table>
<thead>
<tr>
<th>Description</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>126,993</td>
<td>84,178</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>29,161</td>
<td>34,241</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>3,156</td>
<td>3,437</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>159,310</strong></td>
<td><strong>121,856</strong></td>
</tr>
</tbody>
</table>

#### Total liabilities and net assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$282,339</strong></td>
<td><strong>223,985</strong></td>
</tr>
</tbody>
</table>

*See accompanying notes to consolidated financial statements.*
## Consolidated Statement of Activities

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2017  
(with summarized totals for the year ended June 30, 2016) (In thousands)

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total 2017</th>
<th>Total 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operating revenue:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Campaign contributions</td>
<td>$ 237,443</td>
<td>21,077</td>
<td>5</td>
<td>258,525</td>
<td>258,839</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(25,955)</td>
<td></td>
<td></td>
<td>(25,955)</td>
<td>(26,348)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>211,488</td>
<td>21,077</td>
<td>5</td>
<td>232,570</td>
<td>232,491</td>
</tr>
<tr>
<td>Co-Pay contributions</td>
<td>—</td>
<td>77,779</td>
<td>—</td>
<td>77,779</td>
<td>46,379</td>
</tr>
<tr>
<td>Therapy acceleration program contractual return</td>
<td>29,548</td>
<td>—</td>
<td>—</td>
<td>29,548</td>
<td>—</td>
</tr>
<tr>
<td>Donated services, goods and media</td>
<td>14,594</td>
<td>—</td>
<td>—</td>
<td>14,594</td>
<td>11,757</td>
</tr>
<tr>
<td>Legacies and other revenue</td>
<td>5,276</td>
<td>15</td>
<td>—</td>
<td>5,291</td>
<td>7,946</td>
</tr>
<tr>
<td>Service revenue</td>
<td>3,847</td>
<td>—</td>
<td>—</td>
<td>3,847</td>
<td>—</td>
</tr>
<tr>
<td>Net interest and dividend income</td>
<td>2,730</td>
<td>136</td>
<td>—</td>
<td>2,866</td>
<td>1,352</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>78,591</td>
<td>(78,591)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Total operating revenue</td>
<td>372,500</td>
<td>(6,010)</td>
<td>5</td>
<td>366,495</td>
<td>299,343</td>
</tr>
<tr>
<td><strong>Operating expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>65,067</td>
<td>—</td>
<td>—</td>
<td>65,067</td>
<td>54,691</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>125,677</td>
<td>—</td>
<td>—</td>
<td>125,677</td>
<td>89,209</td>
</tr>
<tr>
<td>Public health education</td>
<td>48,138</td>
<td>—</td>
<td>—</td>
<td>48,138</td>
<td>42,881</td>
</tr>
<tr>
<td>Professional education</td>
<td>21,698</td>
<td>—</td>
<td>—</td>
<td>21,698</td>
<td>15,373</td>
</tr>
<tr>
<td>Total program services</td>
<td>260,580</td>
<td>—</td>
<td>—</td>
<td>260,580</td>
<td>202,154</td>
</tr>
<tr>
<td>Supporting services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>29,049</td>
<td>—</td>
<td>—</td>
<td>29,049</td>
<td>27,553</td>
</tr>
<tr>
<td>Fund raising</td>
<td>47,656</td>
<td>—</td>
<td>—</td>
<td>47,656</td>
<td>44,749</td>
</tr>
<tr>
<td>Total supporting services</td>
<td>76,705</td>
<td>—</td>
<td>—</td>
<td>76,705</td>
<td>72,302</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>337,285</td>
<td>—</td>
<td>—</td>
<td>337,285</td>
<td>274,456</td>
</tr>
<tr>
<td>Change in net assets from operating activities</td>
<td>35,215</td>
<td>(6,010)</td>
<td>5</td>
<td>29,210</td>
<td>24,887</td>
</tr>
<tr>
<td>Foreign currency translation adjustment</td>
<td>(180)</td>
<td>(4)</td>
<td>—</td>
<td>(184)</td>
<td>(110)</td>
</tr>
<tr>
<td>Net increase (decrease) in fair value of investments (note 3)</td>
<td>7,780</td>
<td>648</td>
<td>—</td>
<td>8,428</td>
<td>(4,157)</td>
</tr>
<tr>
<td>Net assets transferred and reclassified</td>
<td>—</td>
<td>286</td>
<td>(286)</td>
<td>—</td>
<td>552</td>
</tr>
<tr>
<td>Change in net assets</td>
<td>42,815</td>
<td>(5,080)</td>
<td>(281)</td>
<td>37,454</td>
<td>21,172</td>
</tr>
</tbody>
</table>

## Net Assets:

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of year</td>
<td>84,178</td>
<td>34,241</td>
<td>3,437</td>
<td>121,856</td>
</tr>
<tr>
<td>End of year</td>
<td>$ 126,993</td>
<td>29,161</td>
<td>3,156</td>
<td>159,310</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2017 (with comparative totals for the year ended June 30, 2016) (In thousands)

<table>
<thead>
<tr>
<th>Program Services</th>
<th>Supporting Services</th>
<th>Total</th>
<th>Direct donor benefit costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awards and grants (note 2)</td>
<td>$ 42,219</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Therapy acceleration program (note 2)</td>
<td>4,711</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Clinical trial</td>
<td>2,142</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td>—</td>
<td>1,703</td>
<td>—</td>
</tr>
<tr>
<td>Co-Pay assistance (note 2)</td>
<td>—</td>
<td>72,969</td>
<td>—</td>
</tr>
<tr>
<td>Co-Pay processing fees</td>
<td>—</td>
<td>4,595</td>
<td>—</td>
</tr>
<tr>
<td>Donated services, goods and media (note 7)</td>
<td>4,021</td>
<td>2,563</td>
<td>4,095</td>
</tr>
<tr>
<td>Salaries and employee benefits and taxes (note 9)</td>
<td>5,840</td>
<td>25,488</td>
<td>24,124</td>
</tr>
<tr>
<td>Professional fees</td>
<td>2,946</td>
<td>3,891</td>
<td>4,798</td>
</tr>
<tr>
<td>Printing, advertising, and supplies</td>
<td>97</td>
<td>3,489</td>
<td>3,819</td>
</tr>
<tr>
<td>Occupancy, telephone and insurance (note 10)</td>
<td>367</td>
<td>3,174</td>
<td>2,882</td>
</tr>
<tr>
<td>Travel and meetings</td>
<td>817</td>
<td>2,056</td>
<td>2,329</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td>1,109</td>
<td>1,256</td>
<td>1,209</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>17</td>
<td>1,309</td>
<td>1,878</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>170</td>
<td>1,233</td>
<td>1,026</td>
</tr>
<tr>
<td>Impairment of fixed assets (note 8)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>611</td>
<td>1,951</td>
<td>1,978</td>
</tr>
<tr>
<td>Total expenses</td>
<td>$ 65,067</td>
<td>125,677</td>
<td>48,138</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Cash Flows

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2017  
(with comparative amounts for the year ended June 30, 2016) (In thousands)

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>37,454</td>
<td>21,172</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net (increase) decrease in fair value of investments</td>
<td>(8,428)</td>
<td>4,157</td>
</tr>
<tr>
<td>Impairment of fixed assets</td>
<td>5,434</td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>7,580</td>
<td>6,450</td>
</tr>
<tr>
<td>Provision for uncollectible accounts</td>
<td>188</td>
<td>(445)</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>(707)</td>
<td>3,143</td>
</tr>
<tr>
<td>Contributions and other receivables</td>
<td>(729)</td>
<td>(7,810)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>8,056</td>
<td>(3,320)</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>1,529</td>
<td>197</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>1,112</td>
<td>(4,886)</td>
</tr>
<tr>
<td>Awards and grants payable</td>
<td>3,601</td>
<td>(8,884)</td>
</tr>
<tr>
<td>Co-Pay assistance payable</td>
<td>6,602</td>
<td>(996)</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>61,692</td>
<td>8,778</td>
</tr>
</tbody>
</table>

| **Cash flows from investing activities:** |            |            |
| Purchases of fixed assets              | (6,187)    | (8,570)    |
| Purchases of long-term investments     | (117,279)  | (238,736)  |
| Sales of investments                   | 84,579     | 204,227    |
| **Net cash used in investing activities** | (38,887)   | (43,079)   |
| Net increase (decrease) in cash and cash equivalents | 22,805     | (34,301)   |
| Cash and cash equivalents at beginning of year | 18,596     | 52,897     |
| **Cash and cash equivalents at end of year** | $ 41,401   | $ 18,596   |

See accompanying notes to consolidated financial statements.
1) **Organization and Summary of Significant Accounting Policies**

**A) Organization**

The Leukemia & Lymphoma Society, Inc. (LLS) is the world’s largest voluntary health agency dedicated to finding cures for blood cancers and providing services to blood cancer patients, their families, and caregivers. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today’s most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information regarding blood cancer, and education and support programs. LLS influences public policies that accelerate the development and approval of new blood cancer therapies and advocates for all blood cancer patients and their families, helping patients navigate their cancer treatments and access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

**B) Principles of Consolidation**

The accompanying consolidated financial statements include the accounts of LLS that encompass the National Office of LLS and its fifty-six chapters in the United States, and LLS’s not-for-profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), Beat AML, LLC (BAML) and PearlPoint Cancer Support, Inc. (PPCS). Effective March 28, 2016, LLS became the sole member of PPCS. As part of the assumption of control, LLS recognized a transfer of net assets of $552. All significant inter-company and intra-LLS accounts and transactions have been eliminated in consolidation.

**C) Tax-Exempt Status**

LLS, LLSRP, LLSRF and PPCS qualify as charitable organizations as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, are exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since these organizations are publicly supported, contributions qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

LLSC is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

BAML is a single-member limited liability company and is a disregarded pass-through entity. Accordingly, all revenue and expenses are included in LLS. Income of BAML is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3) consistent with LLS.

LLS and PPCS recognize the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to exempt purposes are subject to tax under Internal Revenue Code Section 511. There were no entities that recognized any unrelated business income tax liability for the years ended June 30, 2017 and 2016.

**D) Estimates**

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, allowance for uncollectible accounts, allocation of expenses, and valuation of donated goods, services and media. Actual results could differ from those estimates.

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2017 (Amounts in thousands)

E) Risks and Uncertainties

LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS’s principal source of revenue is contributions by the general public. Accordingly, LLS’s operations are dependent upon individual contributions, that are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the Co-Pay program in 2017 and 2016 was funded by eight and nine donors, respectively. In addition, the Beat AML Master Trial was primarily funded by five donors in 2017.

F) Summarized Financial Information

The consolidated financial statements are presented with 2016 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2016 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS’s 2016 consolidated financial statements from which the summarized information was derived.

G) Subsequent Events

LLS evaluated subsequent events after the balance sheet date of June 30, 2017 through October 27, 2017, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

H) Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

- **Unrestricted net assets:** Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs or supporting services.
- **Temporarily restricted net assets:** Consist of funds that are restricted by donors for a specific time period and/or purpose.
- **Permanently restricted net assets:** Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds is recorded as temporarily restricted net assets and is released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board-approved spending policy (note 4).

I) Foreign Currency Translation

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

J) Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

- **Level 1 inputs** are quoted or published prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2017 (Amounts in thousands)

Level 2 inputs other than quoted or published prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3 unobservable inputs for the asset or liability.

LLS follows the provisions of Accounting Standards Codification (ASC) §20, Fair Value Measurement, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value (NAV) per share or its equivalent, as reported by the investment managers.

The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.

K) Contributions, Grants and Deferred Revenue

Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

L) Therapy Acceleration Program Contractual Return

In January 2009, as part of its Therapy Acceleration Program (TAP), LLS entered into an agreement with Celator Pharmaceuticals, Inc. (Celator) through which LLS provided funding of approximately $4,100 to Celator in support of the Phase 2 study of Celator’s lead compound Vyxeo™ (daunorubicin and cytarabine liposome for injection) for the treatment of Acute Myeloid Leukemia (AML). From 2012 through 2016, LLS provided funding of an additional $5,000 for the Phase 3 clinical study of Vyxeo™. LLS provisions of funding to Celator were based on clinical milestones.

As part of the agreement, Celator was obligated to make payments to LLS relative to the timing of the product commercialization and other liquidity events. In July 2016, Jazz Pharmaceuticals (Jazz) completed the purchase of Celator, triggering a payment of $13,716 to LLS. In late 2016, Jazz terminated the agreement with LLS triggering a onetime contract termination fee of $11,612 to eliminate potential future royalty payments related to Vyxeo™. The total amount of the return to LLS from its TAP investment in Celator was $25,328.

The remaining $4,220 of TAP contractual return comes from various other TAP investments.

M) Service Revenue

Service revenue is accounted for as an exchange transaction whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

N) Donated Goods and Services

LLS has determined that certain of the donated goods and services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed goods was determined based on fair market value estimates. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These goods and services are recognized as revenue and expense (note 7).

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2017 (Amounts in thousands)

O) Donated Media
LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the consolidated financial statements, was estimated based on the placement, audience, and demographics of the PSAs (note 7).

P) Cash Equivalents
Cash equivalents consist of short-term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

Q) Investments
Investments are stated at fair value based upon quoted or published market prices, except for the fair values of alternative investments which are based on NAVs provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

R) Fixed Assets and Depreciation
Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

S) Other Long-Term Liabilities
Other long-term liabilities represent LLS’s liability for the Internal Revenue Code Section 457 deferred compensation plans recorded at fair market value (note 9) and straight-line rent of office leases (note 10).

T) Professional Fees
Professional fees included in the consolidated financial statements principally include professional fundraising fees, contracted software development, and legal and auditing fees.

U) Reclassifications
Certain reclassifications of 2016 amounts have been made to conform to the 2017 presentation.

2) Research and Co-Pay Assistance Program
LLS has various activities that are utilized to carry out its mission as presented below:

Research
Awards and Grants: Awards and grants for research are approved by LLS’s Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has multi-year grant commitments of $45,410 at June 30, 2017, which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of $64,052 and $60,451 at June 30, 2017 and 2016, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately $923 and $450 as of June 30, 2017 and 2016, respectively, have been netted against awards and grants expense.

(continues »)
TAP: TAP is LLS’s strategic initiative to speed the development of blood cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has contract commitments of $9,144 and $10,214 at June 30, 2017 and 2016, respectively, that are conditioned upon future events and, accordingly, are not recorded.

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows:

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th>2018</th>
<th>2019</th>
<th>2020 and thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$28,702</td>
<td>19,101</td>
<td>6,751</td>
</tr>
<tr>
<td>Total</td>
<td>$54,554</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Co-Pay Assistance Program

Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance Co-Pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expensed in the year approved based on the available funding in the program. Revenue is recognized when the grants are received while expenses are recognized as patients are approved for participation according to program criteria. The Co-Pay Assistance payable of $20,071 and $13,469 has been established based on approved patient applications received through June 30, 2017 and 2016, respectively. At June 30, 2017, temporarily restricted net assets include $8,148 received in 2017, which are available for expenditure and are intended to be awarded in fiscal 2018.

The following summarizes the activities of the Co-Pay Assistance program in 2017 and 2016.

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balance</td>
<td>$8,960</td>
<td>7,254</td>
</tr>
<tr>
<td>Co-Pay contributions</td>
<td>77,779</td>
<td>46,379</td>
</tr>
<tr>
<td>Amount expended during the year:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct assistance to patients</td>
<td>(72,969)</td>
<td>(40,030)</td>
</tr>
<tr>
<td>Other expenses incurred and reimbursed under the contract</td>
<td>(5,622)</td>
<td>(4,643)</td>
</tr>
<tr>
<td>Amounts available for expenditures in the next year</td>
<td>$8,148</td>
<td>8,960</td>
</tr>
</tbody>
</table>

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2017 (Amounts in thousands)

3) Investments

The following tables present LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2017 and 2016:

2017 Level 1 Level 2 Level 3
Money market funds and cash $ 63,155 63,155 — —
Fixed income:
  Corporate bonds 49,312 49,312 — —
  Government securities and other 2,098 2,098 — —
Equities:
  Large cap equity 32,356 32,356 — —
  International equity 30,261 30,261 — —
  Small/mid cap equity 20,813 20,813 — —
  Commodities 3,566 3,566 — —
  Total investments reported at net asset value $ 201,561 $ 201,561 — —
Investments reported at net asset value:
  Multi strategy hedge funds 7,860
Total investments reported at net asset value 7,860
$ 209,421

2016 Level 1 Level 2 Level 3
Money market funds and cash $ 58,704 58,704 — —
Fixed income:
  Corporate bonds 36,228 36,228 — —
  Government securities and other 2,032 2,032 — —
Equities:
  Large cap equity 22,466 22,466 — —
  International equity 20,406 20,406 — —
  Small/mid cap equity 10,429 10,429 — —
  Real estate 5,293 5,293 — —
  Commodities 2,996 2,996 — —
  Total investments reported at net asset value $ 158,554 $ 158,554 — —
Investments reported at net asset value:
  Multi strategy hedge funds 7,503
  Long/short equities 2,236
Total investments reported at net asset value 9,739
$ 168,293

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2017 (Amounts in thousands)

In 2016, LLS transitioned from a traditional Investment custodian to an Outsourced Chief Investment Officer. In this process, LLS liquidated its investment portfolio and reinvested all funds.

Investment expenses totaled $376 and $560 for the years ended June 30, 2017 and 2016, respectively. The unrealized gains were $4,504 and $3,513 for the years ended June 30, 2017 and 2016, respectively.

LLS’s alternative investments are diversified across two investment strategies, as follows:

1. *Multi strategy hedge funds* – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event-driven strategies, distressed debt, merger and other arbitrage, and value investing.

2. *Long/short equities* – primarily investments in funds that, in turn, invest in liquid, marketable securities, attempting to realize gains through the identification of mispriced securities.

These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital balance in each investment.

LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 45–95 days. By contrast, all of LLS’s nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2017 and 2016, the following table summarizes the redemption provisions for those investments reported at NAV:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quarterly</td>
<td>$6,265</td>
<td>6,003</td>
</tr>
<tr>
<td>Annual</td>
<td>1,595</td>
<td>3,736</td>
</tr>
<tr>
<td>Total</td>
<td>$7,860</td>
<td>9,739</td>
</tr>
</tbody>
</table>

As of June 30, 2017 and 2016, LLS had no unfunded commitments on its alternative investments.

4) Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2017 and 2016:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Temporarily restricted</td>
<td>Permanently restricted</td>
<td>Temporarily restricted</td>
<td>Permanently restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time restrictions $6,297</td>
<td>—</td>
<td>272</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research 7,097</td>
<td>3,035</td>
<td>19,377</td>
<td>3,280</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient service 7,533</td>
<td>—</td>
<td>5,367</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Pay assistance 8,148</td>
<td>—</td>
<td>8,960</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other 86</td>
<td>121</td>
<td>265</td>
<td>157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total $29,161</td>
<td>3,156</td>
<td>34,241</td>
<td>3,437</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continues »)
LLS follows the provisions of the New York Prudent Management of Institutional Funds Act, which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2017 and 2016 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS’s overall investment strategy.

The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2017:

<table>
<thead>
<tr>
<th></th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$2,962</td>
<td>3,437</td>
<td>6,399</td>
</tr>
<tr>
<td>Investment income</td>
<td>428</td>
<td>—</td>
<td>428</td>
</tr>
<tr>
<td>Net appreciation</td>
<td>335</td>
<td>—</td>
<td>335</td>
</tr>
<tr>
<td>Contributions</td>
<td>—</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Reclassifications</td>
<td>(347)</td>
<td>(286)</td>
<td>(633)</td>
</tr>
<tr>
<td>Appropriation for expenditure</td>
<td>(252)</td>
<td>—</td>
<td>(252)</td>
</tr>
<tr>
<td>Endowment net assets at June 30</td>
<td>$3,126</td>
<td>3,156</td>
<td>6,282</td>
</tr>
</tbody>
</table>

The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2016:

<table>
<thead>
<tr>
<th></th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$3,086</td>
<td>3,690</td>
<td>6,776</td>
</tr>
<tr>
<td>Investment (loss) income</td>
<td>(164)</td>
<td>64</td>
<td>(100)</td>
</tr>
<tr>
<td>Net appreciation</td>
<td>280</td>
<td>—</td>
<td>280</td>
</tr>
<tr>
<td>Reclassifications</td>
<td>—</td>
<td>(277)</td>
<td>(277)</td>
</tr>
<tr>
<td>Appropriation for expenditure</td>
<td>(240)</td>
<td>(40)</td>
<td>(280)</td>
</tr>
<tr>
<td>Endowment net assets at June 30</td>
<td>$2,962</td>
<td>3,437</td>
<td>6,399</td>
</tr>
</tbody>
</table>
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2017 (Amounts in thousands)

5) Contribution and Other Receivables

LLS’s contribution and other receivables at June 30, 2017 and 2016 consist of unconditional promises to give, receivables associated with service revenue, and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Contributions and other receivables consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>2,749</td>
<td>4,248</td>
</tr>
<tr>
<td>Co-Pay contributions</td>
<td>6,000</td>
<td>6,450</td>
</tr>
<tr>
<td>Other restricted contributions</td>
<td>8,080</td>
<td>6,546</td>
</tr>
<tr>
<td>Service revenue and other</td>
<td>956</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 17,785</strong></td>
<td><strong>17,244</strong></td>
</tr>
</tbody>
</table>

Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate. Amounts are scheduled to be received as follows:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$ 13,688</td>
<td>10,723</td>
</tr>
<tr>
<td>1 to 5 years</td>
<td>5,186</td>
<td>7,272</td>
</tr>
<tr>
<td>After 5 years</td>
<td>25</td>
<td>50</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>18,899</td>
<td>18,045</td>
</tr>
<tr>
<td>Less:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allowance for uncollectible accounts</td>
<td>(357)</td>
<td>(169)</td>
</tr>
<tr>
<td>Discount to present value (1.5% to 5.0%)</td>
<td>(757)</td>
<td>(632)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 17,785</strong></td>
<td><strong>17,244</strong></td>
</tr>
</tbody>
</table>

As of June 30, 2017 and 2016, 53% and 65% of gross legacies and contributions receivable were from two funding sources.
6) Deferred Revenue

The majority of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year end. Deferred revenue as of June 30, 2017 and 2016 consists of the following:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grants</td>
<td>$45</td>
<td>1,145</td>
</tr>
<tr>
<td>Service revenue</td>
<td>2,100</td>
<td>—</td>
</tr>
<tr>
<td>Special events</td>
<td>11,883</td>
<td>11,771</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$14,028</td>
<td>12,916</td>
</tr>
</tbody>
</table>

7) Donated Goods, Services and Media

The value of donated goods, donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donated goods</td>
<td>$3,552</td>
<td>—</td>
</tr>
<tr>
<td>Donated services</td>
<td>2,430</td>
<td>2,867</td>
</tr>
<tr>
<td>Donated media</td>
<td>8,612</td>
<td>8,308</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$14,594</td>
<td>11,175</td>
</tr>
</tbody>
</table>

8) Fixed Assets, Net

Fixed assets at June 30, 2017 and 2016 consist of the following (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold improvements</td>
<td>$1,795</td>
<td>1,434</td>
</tr>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>3,547</td>
<td>3,397</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>36,350</td>
<td>39,706</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>41,692</td>
<td>44,537</td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization</td>
<td>(31,573)</td>
<td>(27,591)</td>
</tr>
<tr>
<td>Fixed assets, net</td>
<td>$10,119</td>
<td>16,946</td>
</tr>
</tbody>
</table>

In 2017, an impairment of fixed assets of $5,434 was recorded for the write-off a fund-raising platform that will no longer be utilized by LLS.
Notes to Consolidated Financial Statements
The Leukemia & Lymphoma Society, Inc. / June 30, 2017 (Amounts in thousands)

9) Retirement Plans

LLS has a defined contribution 403(b) plan covering all employees meeting age and service requirements. LLS contributions are based on a percentage of each eligible employee’s salary and years of service. Expenses under this plan aggregated $2,149 and $1,827 for the years ended June 30, 2017 and 2016, respectively.

LLS has nonqualified deferred compensation plans for its executive staff subject to the provisions of the Internal Revenue Code Section 457 (the 457 Plans). There were no expenses incurred for the years ended June 30, 2017 and 2016. The assets of the 457 Plans are included in investments in the accompanying consolidated balance sheet and amounted to approximately $1,574 and $1,405 at June 30, 2017 and 2016, respectively. The liabilities of the 457 Plans are included in other long-term liabilities in the accompanying consolidated balance sheet and amounted to approximately $1,574 and $1,374 at June 30, 2017 and 2016, respectively.

10) Lease Commitments

The leases for premises, which LLS’s National Office and chapters occupy, expire on various dates through March 31, 2031, and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities.

The approximate minimum aggregate future annual rental commitments are summarized as follows:

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2018</td>
</tr>
<tr>
<td></td>
<td>$7,106</td>
</tr>
</tbody>
</table>

11) Joint Costs Allocation

For the years ended June 30, 2017 and 2016, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$12,832</td>
<td>13,901</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>2,666</td>
<td>2,076</td>
</tr>
<tr>
<td>Public health education</td>
<td>5,002</td>
<td>5,117</td>
</tr>
<tr>
<td>Total</td>
<td>$20,500</td>
<td>21,094</td>
</tr>
</tbody>
</table>
Research Grants

Specialized Center of Research

The Specialized Center of Research Program funds multidisciplinary research by teams of leading-edge academic investigators that hastens the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is comprised of at least three independent research programs that are integrated and supported by scientific core laboratories.

William Carroll, MD, 2014
New York University School of Medicine
Dr. William Carroll is funded in part by Thomas Moore.

Irene Ghobrial, MD, 2014
Dana-Farber Cancer Institute

Helen Heslop, MD, 2014
Baylor College of Medicine

Carl June, MD, 2013
University of Pennsylvania Health System
Dr. Carl June is funded in part by the Cora and John H. Davis Foundation, the Topeka Community Foundation - Advisors Excel Team and an anonymous donor.

Thomas Kipps, MD, PhD, 2014
University of California, San Diego

Tak Mak, PhD, 2017
University Health Network

Ari Melnick, MD, 2016
Weill Cornell Medical College

Stephen Nimer, MD, 2018*
University of Miami

Robert Orlowski, MD, PhD, 2018*
The University of Texas MD Anderson Cancer Center
Andreas Strasser, MSc, FAA, PhD, 2018*
Walter & Eliza Hall Institute of Medical Research

David Weinstock, MD, 2016
Dana-Farber Cancer Institute
Anas Yones, MD, 2017
Memorial Sloan Kettering Cancer Center

The following SCOR grant funding ended during FY17 and was funded, in part or full, by a donor:

- Dr. John Byrd was funded in part by Rita Cavanaugh and Gerald Kafka.
- Dr. Jonathan Licht was funded in part by the Kathryn Dent and John L. Tillman Charitable Fund.

Career Development Program (Scholars and Clinical Scholars)

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Omar Abdel-Wahab, MD, 2017
Memorial Sloan Kettering Cancer Center
Saro Armenian, DO, MPH, 2017
Beckman Research Institute of City of Hope
Uttiya Basu, PhD, 2016
Columbia University Medical Center
Julie Blander, PhD, 2015
Weill Cornell Medical College
Robert Bradley, MD, 2018*
Fred Hutchinson Cancer Research Center
Jan Burger, MD, PhD, 2014
The University of Texas MD Anderson Cancer Center
Dr. Jan Burger is funded in part by David Weinstein.

Fernando Camargo, PhD, 2016
Boston Children’s Hospital
Jianjun Chen, PhD, 2018*
University of Cincinnati
Dr. Jianjun Chen is fully funded by The Marge & Charles Schott Foundation.

Jerry Chipuk, PhD, 2017
ICahn School of Medicine at Mount Sinai
Dipanjani Chowdhury, PhD, 2015
Dana-Farber Cancer Institute
Tomasz Cierpicki, PhD, 2017
University of Michigan
Dr. Tomasz Cierpicki is fully funded by The Jake Wetchler Foundation.

Takeshi Egawa, MD, PhD, 2018*
Washington University School of Medicine in St. Louis
Thomas Fazzio, PhD, 2015
University of Massachusetts Medical School
Benjamin Garcia, PhD, 2016
Perelman School of Medicine at the University of Pennsylvania
Ramiro Garzon, MD, 2016
The Ohio State University

Irene Ghobrial, MD, 2017
Dana-Farber Cancer Institute
Jolanta Grembecka, PhD, 2014
University of Michigan
David Guertin, PhD, 2016
University of Massachusetts Medical School
Katharine Hsu, MD, PhD, 2017
Memorial Sloan Kettering Cancer Center
Morgan Huse, PhD, 2015
Memorial Sloan Kettering Cancer Center
Peng Ji, MD, PhD, 2018*
Northwestern University
Amy Johnson, PhD, 2018*
The Ohio State University
Michael Kharas, PhD, 2018*
Memorial Sloan Kettering Cancer Center
John Koreth, MD, PhD, 2014
Dana-Farber Cancer Institute
Ming Li, PhD, 2015
Memorial Sloan Kettering Cancer Center
Ivan Maillard, MD, PhD, 2014
University of Michigan
Ravindra Majeti, MD, PhD, 2016
Leland Stanford Junior University
Constantine Mitsiades, MD, PhD, 2017
Dana-Farber Cancer Institute
Golam Mohi, PhD, 2014
SUNY Upstate Medical University
Ann Mullally, MD, 2018*
Brigham and Women’s Hospital
Trista North, PhD, 2017
Beth Israel Deaconess Medical Center
Ryan O’Connell, PhD, 2018*
University of Utah
Ryoma Ohi, PhD, 2014
Vanderbilt University Medical Center
Sophie Paczesny, MD, PhD, 2015
Indiana University

*Newly awarded or renewed grants in Fiscal Year 2018
Christopher Park, MD, PhD, 2018*
New York University School of Medicine
Talya Salz, PhD, 2014
Memorial Sloan Kettering Cancer Center
Joseph Scandura, MD, PhD, 2014
Weill Cornell Medical College
Xiaobing Shi, PhD, 2017
The University of Texas MD Anderson Cancer Center
Daniel Starczynowski, PhD, 2016
Cincinnati Children’s Hospital Medical Center
Kimberly Stegmaier, MD, 2014
Dana-Farber Cancer Institute

Hans-Guido Wendel, MD, 2015
Memorial Sloan Kettering Cancer Center
Dr. Hans-Guido Wendel is funded in part by Susan Reid.
Johnathan Whetstone, PhD, 2015
Massachusetts General Hospital
Catherine Wu, MD, 2015
Dana-Farber Cancer Institute
Xiaochun Yu, MD, PhD, 2015
Beckman Research Institute of City of Hope
Shan Zha, MD, PhD, 2014
Columbia University Medical Center
Chengcheng Zhang, PhD, 2014
The University of Texas Southwestern Medical Center
Jing Zhang, PhD, 2014
University of Wisconsin
Xiaolan Zhao, PhD, 2014
Memorial Sloan Kettering Cancer Center

Dan Dominissini, PhD, 2016
The University of Chicago
Shannon Elf, PhD, 2018*
Brigham and Women’s Hospital
Jonathan Eisenstein, MD, PhD, 2017
University of California, San Francisco
Dr. Jonathan Eisenstein is funded in part by an anonymous donor.

Dr. Dhaval Dhru.
Dr. Shannon Oda is fully funded by Dr. Dhaval Dhru.

Talya Salz, PhD, 2014
Memorial Sloan Kettering Cancer Center
Joseph Scandura, MD, PhD, 2014
Weill Cornell Medical College
Xiaobing Shi, PhD, 2017
The University of Texas MD Anderson Cancer Center
Daniel Starczynowski, PhD, 2016
Cincinnati Children’s Hospital Medical Center
Kimberly Stegmaier, MD, 2014
Dana-Farber Cancer Institute

Christopher Vakoc, MD, PhD, 2016
Washington University School of Medicine
Loren Walensky, MD, PhD, 2015
Cold Spring Harbor Laboratory
Yuanyu Wang, MD, PhD, 2015
Benaroya Research Institute
Daniel Starczynowski, PhD, 2016
Cincinnati Children’s Hospital Medical Center

Geoffrey Uy, MD, 2018*
Washington University in St. Louis
Christopher Vakoc, MD, PhD, 2016
Cold Spring Harbor Laboratory
Loren Walensky, MD, PhD, 2015
Dana-Farber Cancer Institute
Matthew Walter, MD, 2014
Washington University School of Medicine in St. Louis
Roland Walter, MD, PhD, MS, 2015
Fred Hutchinson Cancer Research Center
Dr. Roland Walter is fully funded by Dr. Dhaval Dhru.
Wenqi Wei, PhD, 2014
Beth Israel Deaconess Medical Center
David Weinstein, MD, 2014
Dana-Farber Cancer Institute

Shruti Bhatt, PhD, 2017
Dana-Farber Cancer Institute
George Burslem, MS, PhD, 2018*
Yale University
Sheng F. Cai, MD, PhD, 2017
Memorial Sloan Kettering Cancer Center
Hye J Cha, PhD, 2017
Boston Children’s Hospital
Huan Chen, PhD, 2017
Boston Children’s Hospital
Ryan Corces, PhD, 2018*
Leland Stanford Junior University
Ahmet Coskun, PhD, 2016
Leland Stanford Junior University
Madzia Crossley, PhD, 2017
Leland Stanford Junior University
Ana Carolina da Silva Almeida, PhD, 2017
Columbia University Medical Center
Sarah Deng, PhD, 2017
New York University Medical Center

Neeraj Joshi, MSc, PhD, 2016
University of California, San Francisco
Yoon-A Kang, PhD, 2018*
Columbia University Medical Center
Richard Jason Lamontagne, PhD, 2018*
The Wistar Institute
Fides Lay, PhD, 2017
University of California, Los Angeles
I-Ju Lee, PhD, 2016
Dana-Farber Cancer Institute
Stanley Lee, PhD, 2017
Memorial Sloan Kettering Cancer Center
Dr. Stanley Lee is funded in part by an anonymous donor.

Qiming Liang, PhD, 2016
Shanghai Institute of Immunology
Rusting Lin, PhD, 2018*
Emory University
Priya Mathur, PhD, 2018*
The University of Chicago
Lucia Morgado Palacin, PhD, 2018*
Columbia University Medical Center

*Newly awarded or renewed grants in Fiscal Year 2018

2017 ACKNOWLEDGEMENTS
The following CDP grant funding ended during FY17 and was funded, in part or full, by a donor:

- Dr. Christopher Cogle was funded in part by the Kathryn Dent and John L. Tillman Charitable Fund.
- Dr. Irene Ghobrial was funded in part by the Kathryn Dent and John L. Tillman Charitable Fund.
- Dr. Saad Usmani was funded in part by the Carolinas Healthcare Foundation.

Translational Research Program

The Translational Research Program supports outstanding investigators deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients’ lives.

Ricardo Aguas, MD, PhD, 2017
The University of Texas Health Science Center at San Antonio

Iannis Atlantis, PhD, 2016, 2017
New York University School of Medicine

Translational Research Program

The Translational Research Program supports outstanding investigators deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients’ lives.

Ricardo Aguas, MD, PhD, 2017
The University of Texas Health Science Center at San Antonio

Iannis Atlantis, PhD, 2016, 2017
New York University School of Medicine

*Newly awarded or renewed grants in Fiscal Year 2018
**Translational Research Program: Renewal**

John Byrd, MD, 2015
The Ohio State University
Maria Figueroa, MD, 2017
University of Miami
Steven Grant, MD, 2017
Virginia Commonwealth University
Ronald Hoffman, MD, 2017
Icahn School of Medicine at Mount Sinai
James Rubenstein, MD, PhD, 2017
University of California, San Francisco
Dr. James Rubenstein is funded in part by Leon Barchers and Lisa Scheer & Ed Cone
Steven Treon, MD, PhD, 2018
Dana-Farber Cancer Institute
Li Zhang, MSc, MD, PhD, 2018
University Health Network
The following TRP grant funding ended during FY17 and was funded, in part or full, by a donor.
- Dr. Richard Jones was funded in part by The Charles T. Bauer Charitable Foundation.
- Dr. Javier Pinilla was funded in part by Dorothy Fields.
- Dr. Roland Walter was fully funded by Dr. Dhaval Dhru (included in CDP section)

**MPN Challenge Grants**

This program is run in partnership with the MPN Research Foundation.

Angela Fleischman, MD, PhD, 2018
University of California, Irvine
James Griffin, MD, 2018
Dana-Farber Cancer Institute
Vivian Oehler, MD, 2018
Fred Hutchinson Cancer Research Center

**IWMF Grants**

This is a program run in partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF).

Shahrzad Jalali, PhD, 2018
Mayo Clinic
Larry Kwak, MD, PhD, 2018
Beckman Research Institute of City of Hope
Sherie Morrison, PhD, 2018
David Geffen School of Medicine at University of California, Los Angeles
Bruno Palva, PhD & Jose Angel Martinez Climint, MD, 2018
University of Navarra
Marzia Varettoni, MD, 2018
Fondazione Italiana Linfomi Onlus

**Special Initiatives**

Ari Melnick, MD, 2015
Weill Cornell Medical College
Dr. Ari Melnick is funded in part by the Paul E. Singer Foundation Innovation Grant in DLBCL.

Markus Muschen, MD, PhD, 2017
Beckman Research Institute of City of Hope
Dr. Markus Muschen is funded in part by the Dr. Ralph and Marian Folk Medical Research Trust.

**New Idea Award**

A concept award that funds innovative approaches that may fundamentally change the understanding, diagnosis and/or treatment of blood cancers and related premalignant conditions.

- Dr. Craig Crews' funding ended during FY17 but he was funded in part by Dr. Nadia Christensen.

**Screen to Lead Program**

Adolfo Ferrando, MD, PhD, 2018
Columbia University Medical Center
Gary Reuther, PhD, 2018
H. Lee Moffitt Cancer Center & Research Institute

**Rising Tide Foundation for Clinical Cancer Research/LLS Patient-Focused Immunotherapy Initiative**

David Gottlieb, MD, 2017
The University of Sydney
Ann Leen, PhD, 2017
Baylor College of Medicine
Ronald Levy, MD, 2017
Leland Stanford Junior University
Margaret Shipp, MD, 2017
Dana-Farber Cancer Institute

**Transforming CURES Initiative**

John Crispino, PhD, 2016
Northwestern University
Reuben Kapur, PhD, 2016
Indiana University – Purdue University Indianapolis
Phillip Koeffler, MD, 2016
Cedars-Sinai Medical Center
Akko Shimamura, MD, PhD, 2016
Boston Children’s Hospital

*Newly awarded or renewed grants in Fiscal Year 2018
Partnerships

**Therapy Acceleration Program Partnerships**

- Acetylon Pharmaceuticals, Inc Boston, MA
- Affimed Therapeutics AG Heidelberg, Germany
- BioTheryX, Inc. Chappaqua, NY
- Ivan Borrello, MD Johns Hopkins University
- Sidney Kimmel Comprehensive Cancer Center
- Celator Pharmaceuticals, Inc Princeton, NJ
- Constellation Pharmaceuticals, Inc Cambridge, MA
- Giulio Draetta, MD, PhD The University of Texas MD Anderson Cancer Center
- Brian Druker, MD Oregon Health & Science University
- Forty Seven, Inc. Menlo Park, CA
- Irene Ghobrial, MD Dana-Farber Cancer Institute
- ImmunGene, Inc. Camarillo, CA
- Anand Jillella, MD Emory University
- Kiadis Pharma NV* Amsterdam, Netherlands
- Kite Pharma, Inc. Santa Monica, CA
- Ronald Levy, MD The Board of Trustees of the Leland Stanford Junior University
- OncoPep, Inc. North Andover, MA
- Daniel Pollyea, MD University of Colorado
- Stemline Therapeutics, Inc. New York, NY

* Equity investment of $750,000 in Fiscal Year 2017.

**Advisors**

**Medical & Scientific Affairs Committee**

- Steve Rosen, MD, FACP* Beckman Research Institute of City of Hope Chair
- Stephen Ansell, MD, PhD Mayo Clinic, Rochester
- Leif Bergsagel, MD Mayo Clinic, Arizona
- Ravi Bhatia, MD The University of Alabama at Birmingham
- Renzo Canetta, MD* former BMS
- Alan D’Andrea, MD Dana-Farber Cancer Institute
- Giulio Draetta, MD, PhD The University of Texas MD Anderson Cancer Center
- Philip Frost, MD, PhD former Imclone, Wyeth
- Irene Ghobrial, MD Dana-Farber Cancer Institute
- Catriona Jamieson, MD, PhD University of California, San Diego
- Larry Kwak, MD, PhD Beckman Research Institute of City of Hope
- Michelle LeBeau, PhD The University of Chicago
- Ross Levine, MD Memorial Sloan Kettering Cancer Center
- Jonathan Licht, MD University of Florida
- Alan List, MD H. Lee Moffitt Cancer Center & Research Institute
- Susan O’Brien, MD University of California, Irvine
- Franklin O. Smith, III, MD* MedPace

**Therapy Acceleration Program Advisors**

- Dana Callow, MBA Boston Millennia Partners Chair
- Adam Craig, MBBS, PhD Medarc Consulting
- C. Casey Cunningham, MD Santé Ventures
- William Dalton, MD, PhD M2Gen
- Giulio Draetta, MD, PhD The University of Texas MD Anderson Cancer Center
- Ross Levine, MD Memorial Sloan Kettering Cancer Center
- Ronald Levy, MD The Board of Trustees of the Leland Stanford Junior University
- Vern Norviel, JD Wilson Sonsini Goodrich & Rosati
- Susan M. O’Brien, MD The University of California, Irvine
We are pleased to recognize the extraordinary involvement of individuals, companies, corporations and organizations in their support of LLS and its mission. Those honored give of their time, talent and have made a significant difference in the lives of so many. To find out more about our awards program, please go to http://www.lls.org/national-awards-nomination

Congratulations to all the 2017 awardees!

2017 National Recognition & Awards Program

Vision for Life Award
Individual, corporation, or organization who, by thinking outside of the box, helped to create a new national campaign or program.

Rob Braley
Mississippi & Louisiana Chapter
Gary Jobson
Maryland Chapter
Frank N. Moore, MD, CellCycle
Rocky Mountain Chapter

Dr. John J. Kenny Award
Member of medical community, a social worker, or a caregiver who supports patient services.

Matthew J. Matasar, MD
Long Island Chapter
Jeffrey V. Matous, MD
Rocky Mountain Chapter
Kim Schuetz
Wisconsin Chapter
Marin Xavier, MD
San Diego & Hawaii Chapter

Dr. Kenneth B. McCredie Award
Individual or corporation who has supported LLS for at least 5 years and helped raise more than $1 million.

Ray Authement, PhD
Mississippi & Louisiana Chapter
Imagine A Cure for Leukemia
LLS Canada
Lynne O’Brien
National Capital Area Chapter
PFG/Vistar
Rocky Mountain Chapter

Terumo BCT
Rocky Mountain Chapter
The van Wieringen Family
Wisconsin Chapter

Partners Against Blood Cancer Award

Ruby (40+ years)
Sigma Alpha Epsilon – Georgia Beta
Georgia Chapter

Platinum (20+ years)
Melissa Abdouch
Minnesota Chapter
Wayzata Central Middle School
Minnesota Chapter
Wheel & Sprocket
Wisconsin Chapter

Gold (15+ years)
680 The Fan
Georgia Chapter

Silver (10+ years)
Cardinal Solutions Group
Tri-State Southern Ohio Chapter
Hoxworth Blood Center
Tri-State Southern Ohio Chapter
The Jewish Hospital - Mercy Health
Tri-State Southern Ohio Chapter
Norton Healthcare
Kentucky & Southern Indiana Chapter

Chairman’s Awards

Chairman’s Advocacy Citation
Pennsylvania State Representative Matt Baker - Chairman, Pennsylvania House of Representatives Health Committee Central Pennsylvania Chapter

Chairman’s Leadership Citation
Wayne Berson
National Capital Area Chapter
Tam Driscoll
Oregon SW Washington Idaho Montana Chapter
James P. Joseph
Long Island Chapter
Tony Lubrano
Long Island Chapter
Jason Ryan
Texas Gulf Coast Chapter
Don Ed Wright
South Central Texas Chapter
Special Recognition Citation

Guy Briere
Mississippi & Louisiana Chapter
Lisa Cooper
Greater Bay Area Chapter
Robert Covay
Greater Bay Area Chapter
Matt Eicheidinger
Minnesota Chapter
Chris Flores - League Champion
South Central Texas Chapter
Douglas Grimmelt
Long Island Chapter
Chris Kegel
Wisconsin Chapter
John King
Kentucky & Southern Indiana Chapter
The LIUNA Charitable Foundation
National Capital Area Chapter
Rachel Peniche
San Diego & Hawaii Chapter
Bill Rawlings
Georgia Chapter
Chris Wilson
Central California Chapter
Richard T. Wright
Western & Central New York Chapter
Casey Zylla
Minnesota Chapter

2017 Media Awards Recipients

Recipients have a record of excellence in promotional support & fundraising, as well as educating and informing the public of the LLS organization and its mission.

Digital

CARAT
New York, NY
Jim McKinnis
The Integer Group
Dallas, TX

Radio

Cox Media Group
K991, WHKO-FM
Dayton, OH
Anna de Haro
iHeartMedia, Inc.
Dallas, TX
Josh Delozier
TheSpy - KOSU-FM
Oklahoma City, OK
iHeartMedia, Inc.
Dallas, TX
iHeartMedia, Inc.
Tempe, FL
iHeartMedia, Inc.
100.3 FM - WHTZ
New York, NY
Skeery Jones
Z100 Elvis Duran & the Morning Show
iHeartMedia, Inc.
New York, NY
KRMG
Tulsa, OK
myTalk 1071
KTMX-FM
St. Paul, MN
Sam Nein
iHeartMedia, Inc.
Tampa, FL
Andie Summers
92.5 XTU
Philadelphia, PA
Alexis Thompson
myTalk 1071
KTMX-FM
St. Paul, MN
Nancy Wilson
Cox Media Group
K991, WHKO-FM
Dayton, OH
92.5 XTU
WXTU-FM
Philadelphia, PA

Print

Biz New Orleans
Metairie, LA
Pam Deller
Lehigh Valley Style
Palmer Township, PA
Fort Worth Business Press
Fort Worth, TX
Lehigh Valley Style
Palmer Township, PA
Pat Selcer
Lamar Advertising Company
Tulsa, OK
Tyler Media Group
Oklahoma City, OK
Lamar Advertising Company
Guaynabo, Puerto Rico

Television

ABC 8News - WRIC-TV
Richmond, VA
Barclay Bishop
WJBF NewsChannel 6
Augusta, GA
Leslie Bohl
WOAI-TV
News 4 San Antonio Today
San Antonio, TX
Eric Braate
KPRC 2
Houston, TX
Drew Carney
KGW-TV, NewsChannel 8
Portland, OR
CBS6 - WTVR-TV
Richmond, VA
Doug Dunbar
KTVT-TV, CBS 11 News
Fort Worth, TX
Fire on the Bayou
New Orleans, LA
FOX23 News - KOKI-TV
Tulsa, OK
Laura French
CBS6 - WTVR-TV
Richmond, VA
Good Day Street Talk
Fox 5 NY
New York, NY
Karen Grace
KENS 5 Eyewitness News
San Antonio, TX
Sonya D. Heitshusen
WHO-TV Channel 13
Des Moines, IA
KDFW - FOX 4 News
Dallas, TX
KENS 5 Eyewitness News
KENS-TV
San Antonio, TX
KGW-TV, NewsChannel 8
Portland, OR
KMBC 9 News
KMBC-TV
Kansas City, MO
KMOV Channel 4
KMOV-TV, CBS
St. Louis, MO
KPRC 2
Houston, TX
KTVT-TV, CBS 11 News
Fort Worth, TX
John Kukla
KDFW-TV
Dallas, TX
Clay Loney
FOX23 News
Tulsa, OK
Larry Michael
Washington Redskins
Ashburn, VA
Larry Moore
KMBC 9 News
Kansas City, MO
NBC10 Philadelphia
WCAU-TV
Bala Cynwyd, PA
Kerri O’Brien
ABC 8News - WRIC-TV
Richmond, VA
Joe Silvestri
Good Day Street Talk
Fox 5 NY
New York, NY
Tina Stoklosa
NBC10 Philadelphia
Bala Cynwyd, PA
Eileen Whelan
WILLA NewsChannel 8, ABC7
Arlington, VA
WHO-TV Channel 13
Des Moines, IA
The Volunteer Leadership Conference 2017 Elite Award Recipients

Recognize outstanding contributions and achievements of a select group of LLS volunteers and organizations making an extraordinary impact for LLS and its mission.

Philanthropy Award

Individual, family, or foundation that demonstrates outstanding philanthropic leadership in support of LLS Mission.

Michael Copley
Chairman, LLS’s Beat AML Campaign

John Kellenyi
Vice Chairman of LLS’s Beat AML Campaign

Patti Robinson Kaufmann Spirit Award

An incredible patient access volunteer and survivor.

Theresa Stevens
San Diego/Hawaii Chapter

Robert de Villiers Award

The highest honor and pinnacle of achievement for a volunteer, named after the son of LLS’s founders.

Dave Frantze
Mid America Chapter

Other

Mark Romig
New Orleans Tourism & Marketing Corporation
New Orleans, LA

Sidney D. Torres, IV
IV Capital
New Orleans, LA

The Excellence in Policy Advocacy Award

Volunteers who have successfully advocated for policy changes that will have a real impact on blood cancer patients.

Kathy Hawkins
Central Pennsylvania Chapter

Volunteer Leadership Award

Recognizes a volunteer with exemplary leadership and extraordinary dedication to LLS and its mission.

Brad Vick
Minnesota Chapter

Pinnacle Award

Individual who has demonstrated exceptional leadership, dedication, and extraordinary commitment to LLS campaign fundraising efforts and the overall LLS mission.

John Greene
Greater Bay Area Chapter

National Corporate Leadership Award

Corporation/organization with fundamental alignment to the LLS mission.

United Food and Commercial Workers

Kaufmann Spirit Award

An incredible patient access volunteer and survivor.

Theresa Stevens
San Diego/Hawaii Chapter

Robert de Villiers Award

The highest honor and pinnacle of achievement for a volunteer, named after the son of LLS’s founders.

Dave Frantze
Mid America Chapter
We gratefully acknowledge the individuals, foundations and corporations that generously supported LLS’s mission during this fiscal year.

## Donors

We gratefully acknowledge the individuals, foundations and corporations that generously supported LLS’s mission during this fiscal year.

### Champion

$500,000 - $999,999

- Amgen, Inc.
- Barclays
- BMC
- Elbit Systems of America
- Lang/Stiglitz Family Fund
- Kathryn and Rush Limbaugh
- Pfizer, Inc.
- PVH
- Sarah Cannon Blood Cancer Network
- Subaru of America, Inc.
- Teva Pharmaceuticals

### Patron

$100,000-$249,000

- 7 Eleven Alon
- ADF Companies - Pizza Hut
- Aetna
- James Allen
- Alto-Shaam, Inc.
- Ameren Missouri
- Anthem Blue Cross Blue Shield
- Astellas
- At Home
- BD
- Blue Cross and Blue Shield
- The Boldt Family Philanthropy Fund*
- Dr. Evelyn Bata
- Bristol-Myers Squibb
- Burlington
- Celgene Corporation
- Cynthia and Frank Gasztory*
- Genentech/Biogen
- Gilead Sciences, Inc.
- The Harry T. Mangurian, Jr. Foundation*
- LIUNA Charitable Foundation*
- The Norcross Foundation, Inc. In Memory of Herrick F. Norcross, Jr. (Rick)*
- The Olive Garden Italian Restaurant
- Pharmacyclics/Janssen
- Donald Porteous*
- Salesforce
- The Sarah Cannon Fund at the HCA Foundation*
- Takeda Oncology
- The United Food and Commercial Workers International Union (UFCW)
- The United Food and Commercial Workers International Union Canada/TUAC
- Walgreens

### Visionary

$250,000 - $499,999

- Advisors Excel Team
- BDO USA, LLP
- Bloomberg
- Carolinas Healthcare Foundation*
- Carter's, Inc.
- Circle of Service Foundation*
- Dhaval Dhru
- Discount Tire
- The Dougherty Family Foundation
- Marian Dozier*
- Dr. Ralph & Marian Falk Medical Research Trust
- Charles Esten*
- FIS
- Global Franchise Group
- Goldman Sachs
- The Herman O West Foundation
- IHOP
- Incyte Corporation
- John B. Kellenyi (Late)
- Kite Pharma
- Christine and Timothy Lindenfelser*
- Nike
- Novartis Pharmaceuticals
- Orokawa Foundation
- Perfumania

### Renaissance Charitable Foundation, Inc.

- Rising Tide
- Floyd Singleton
- Stater Bros. Charities
- Trust
- Wells Fargo
- Western Digital

### Innovator

$50,000-$99,999

- 14 Foods / Dairy Queen
- ABM Onsite Services, Inc.
Agios Pharmaceuticals, Inc. All Round Foods Bakery Products, Inc.
Allegheny Foundation American Airlines Anthemic, LLC
The Arthur M. Blank Family Foundation AstraZeneca Pharmaceuticals Bank of America/Merrill Lynch
Anthony Becht The John and Frances Beck Family Foundation
C. Kenneth & Laura Baxter Foundation, Inc. The Blackstone Charitable Foundation
C.J. Coakley Inc. Cancer Treatment Centers of America
CareFirst BlueCross BlueShield Ron Cohn
Comcast Communities Foundation of Texas Community Visionary Enterprises
David Yurman Dominon
Enmark Stations, Inc. First NBC Flamingo, Inc.
Ethis and Bernard Garil Generac Power Systems Gexa Energy
Neda Ghahremani Guggenheim Life and Annuity
Hargrove Hildegarde D. Becher Foundation Inc.
Infor Global Solutions The J. Willard & Alice S. Marriott Foundation
Hamilton E. James Jerome S. & Grace H. Murray Foundation
Jersey Mike’s Subs Johnson & Johnson
Gerald Kafka & Rita Cavanagh Richard Kay
Kent’s Run Emily and Neil Kustomer Kolache Factory
Koppers
Paul Leinwand Lighthouse Investment Partners, LLC
Louisville Metro Government Donna Lyon
Mallinckrodt Pharmaceuticals McKesson Specialty Health
Medical Mutual Mercer
Thomas Moore Moppie’s Love
Kevin Morris Tommy Morrison
Northrop Grumman Northwestern Mutual - Minneapolis
NYCB Pacific Union
Pamela B. Katzen Memorial Leukemia Research Foundation
Ping Y. Tai Foundation, Inc. Postage Stamp Farm Foundation
PRG Rampart High School
Amber and Tim Randolph Suhail and PJ Rizvi
Robert E. Gallagher Charitable Trust Janet and Martin Robertson
Nancy and Richard Rogers
Scott Safety David Salmanowitz
Sanofi-Aventis U.S., LLC Savera Charitable Trust
Linda Schwartzstein* Stephen A. Schwartzman
Lauree and Robert Simmons Mary Elizabeth and George Smith
Southwestern Ohio Wendy’s Starfish Foundation
Todd Reed McClintock Research Foundation
Sidney Torres, IV Trevor Loughlin Foundation Inc.
UC Irvine Health Care UPMC
Kathryn and Leo Vecello
The Victor E. and Caroline E. Schutte Foundation - Trust E
Walmart
Angie and Don Ward Washington Area Mercedes-Benz Dealers/Mercedes-Benz USA, LLC
The Wellmark Foundation

Advocate $25,000-$49,999
27th Group Accredited Home Lenders Foundation Fund
Akin Gump Strauss Hauer & Feld, LLP
Alex and Ani
The Alice Lawrence Foundation, Inc. Patrick Allender
Allstate Insurance Company
Alverin M. Cornell Foundation
American Systems
Madeline and Stephen Anbinder
Jean and C.E. Andrews
Angel Wings Foundation
James Bailey and Roann Costin
Bank of America
Barreto Family
Kspar Basse
Baylor Scott & White
BB&T
Benchmark Rehabilitation
Bert Smith & Co. Certified Public Accountants
Beta Engineering
Black Dog Charity
Susan and Ed Blumenfeld
Bob Ruth Ford, Inc.
Bon Secours St Francis Cancer Center
Melvin and Valerie Booth
Leon and Michael Borchers*
Bowlman T. Bowles
Brayton Purcell, LLP
Breeden-Adams Foundation
Todd Brinkmeyer
Pamela and Morris Brown
BTIG, LLC
Jeff Burch
C.H. Robinson Worldwide
Capital One
Michael Capone
Carlos Batista Foundation
Carlson Family Foundation, Inc.
Carz Cruzin, INC.
Casino Arizona
CB Richard Ellis-N.E. Partners, LP
Kathy and Sammy Cemo
Centene Corporation
The Chambers Family Foundation

The Charles T Bauer Charitable Foundation
Chesmar Homes CT, LTD.
Circle City Foundation
Cleveland Clinic
Cohn Family Foundation
CohnReznick
The Colton Company
Comer
Community Foundation of New Jersey
Community Foundation Sonoma County
Currie Garner Family Fund
Daiichi Sankyo
Dana-Farber Cancer Institute
David F. Weeda Foundation
David M. Polen Retirement Plan Trust
Dealer Tire
Del-Camp Investments Inc.
Delltek, Inc.
Digitas Health Philadelphia
Edith M. Schweekendieck Trusts
Edward B. Dunlap, Jr Foundation
The Edward G. & Kathryn E. Mader Foundation
EFESTE
Equestrian Sport Productions, LLC
Everyday Health, Inc.
Ezralow Family Trust
FarmHouse Fraternity- Troy University
Fernandez Foundation, Inc.
First Weber Group Foundation
Florida Power & Light Company
For Julie Foundation, Inc.
Forward Advantage Foundation, Inc.
The Foundation at Rolling Hills
Chad Freampton
Franklin American Mortgage Company
Garden City Turkey Trot Race Committee, Inc.
General Dynamics Information Technology
Patricia and Chris Giannoulas
GIANT Food
Greehey Family Foundation
Rachel and Eric Green
Hacksack University Medical Center
Jen Hall
The Handlery Foundation
Hannig Law
Pete Harman
The Harry and Jeanette Weinberg Foundation, Inc.
Hazmat/Kenworth
Heartland Blood Centers
Higgins Family Charitable Foundation
Highland Park Village
Highmark
Al Hill Jr.
David Hitz
Howard Family Foundation
Huntsman, LLC
Niles Hushka
Hy-Vee, Inc.
ICAP Services North America, LLC
iHeartRadio
In Loving Memory of Betty Karpinski
J Frank Schmidt Family Charitable Foundation
J.T. Tai & Co. Foundation, Inc.
Scott Jackson
Jersey Mike’s Corporate Advertising Fund
Jessica Drew Sunshine Memorial Fund
The Jim Jacobs Charitable Fund
Jessica Drew Sunshine Memorial Fund
The Jim Jacobs Charitable Fund
John Theurer Cancer Center
Cynthia & Dan Johnson
Kaiser Permanente Financial SVCS
OPS
The Kakaty Family
Susan and Daniel G. Kane
Tammy Karnes
Keller Williams Realty McLean
Kent Island American Legion
The Keri Shull Team
David Kopp
Kosair Charities Committee, Inc.
Kroger Co. Foundation
The Kroil Family Foundation
Don C. and Diane S. Lake Family
Legacy Mutual Mortgage
Eugene Lewaniak
Lilly USA, LLC
Lindy Paving
Lockton Companies, LLC
Louisville Jefferson County Metro Government
Amanda and Jody Lucero
Lunardi’s Market
Luppe & Paula Luppen Family Foundation
M&T Bank & Wilmington Trust
Macquarie Group
West Marine
The Mark Becher Family Giving Fund
Paula and Larry Marshall
Mason City School District
Massapequa Turkey Trot, Inc
MAXMUS Foundation
Mazda North American Operations
McKesson Specialty Care Solutions
Medical Properties Trust
Memorial Healthcare
Melyder Foundation*
Merck Foundation
Mobile Beacon
Janice Moran
Morgan, Lewis & Bockius, LLP
Jack Morkan and Clare Vanderbeek
Beverly and Stephen Movius
Mud Pie
MUFG Union Bank Trust Dept
North Bay Cancer Alliance
Northside Hospital
Notre Dame Academy High School, Inc.
Jerome Oakey and Laura Randolph
Otsuka America Pharmaceutical, Inc.
PennMedicine
Peoples Natural Gas
Stephanie and Scott Petty
PF GeVista
Philadelphia Multiple Myeloma Networking Group
Plaid Pantries, Inc.
Planned Systems International
Plastics Industry Association
Poker Central, LLC
Princeton University
PricewaterhouseCoopers
Publicis Health Media
QuintilesIMS
The Randy and Barbara Ann Frankel Foundation
J. Miles Reidy
Riemer & Braunstein, LLP
Robbins Family Foundation
The ROMA Foundation
Ronald Caporale
Debra Ross
RSM US Foundation
Joan and Paul Rubschlager
Runners for Life
Runners for Life Houston, LLC
The Ryan Foundation
Pat and Jeff Sachs*
SAIC
San Jose Earthquakes
Arlene Schafer
Schafer Family Foundation
Helena Scott
Seedings Foundation
Sempria Energy Foundation
Sentrillion, LLC
Shlomo and Tamar Rechnitz Charity Foundation
Shire
Sidley Austin, LLP
Solutionreach, Inc.
St. Joseph’s/Candler Hospital
Donald Steiner
The Stephen Birobaum Foundation
Stomont - Vail, Inc.
Michael Sweig
Sylvan Laureate Foundation
Texas Capital Bank
Texas Oncology
Thunderbirds Charities
Tigerfliht
Baker Tilly
Toys R Us Children’s Fund
Treen Events
UF Cancer Center at Orlando Health
UNC REX Healthcare
United Way of Greater Milwaukee
UPS
Valero Energy Foundation
Vanda Pharmaceuticals Inc.
Venable, LLP
Phil Venables
Virginia Sheldon Jerome Foundation
Michael Vlock
Vystar Credit Union
W.R. & Norma Ramsey Foundation
VF Corporation
VF Corp
VF Foundation
Wet Willie’s Management Corp.
The William J. Shaw Family Foundation
William R. Rich Foundation
Brenda and James Wishbow
Donna and Glen Wolther
WTOP Radio
Anonymous (4)

Giving Circle
$10,000-$24,999

Abacus Technical Services, LLC
ABC 7/WJLA-TV
Daniel and Megan Abein
Acadia Realty Limited Partnership
Accel
Accenture
Access Point, Inc.
Accord Healthcare, Inc.
Accountable Health Solutions
Accura Calibration
The ACE Family Foundation
Ann Milton Adams
Adagio Pharmaceuticals
AEG Global Partnerships
Agency Rx, LLC
Isaac Alba
Air Products Foundation
Evelyn Akers
Alamo Group
Albany Rods and Kustoms, Inc.
Albertsons Safeway
Albertrecht Family Foundation
Alliance Construction Group
Alliance Data
Alliant Insurance Services, Inc.
Allison-Smith Company
Almond & Company, LLC
Allstate Foundation
The Altshul Foundation
AM Charity Fund
Amegy Bank
American Construction Company
American Direct Marketing Resources LLC
American Electric Power
American Insurance Group
AmeriSourceBergen Foundation
The Tarang and Hirni Amin Family Fund
AmTrust Bank/NYCB
David & Barbara Dehaemers  
Jason Dehaemers  
Dekker/Perich/Sabatini, Ltd  
Delta Dental  
Demolition and Environmental Company, LLC  
Denver Beer Olympics  
Denver Region Toyota Dealers Association  
DEPCOM Power  
Robert Dickinson  
Joseph Dimenna  
Dittmar Company  
The Division of Hematologic Malignancies and Cellular Therapeutics  
DLE Equipment  
DoMyOwnPestControl.com  
Lucy and Bob Donahue  
William J. Dore  
Paul Dorman  
Mary Jo Dougherty and Mike Roark  
Doylestown Health Cancer Institute  
Driscol’s  
Max Duckworth  
Duke Cancer Institute  
Milane Duncan-Frantz  
Dyer Family Foundation  
The E. Kenneth And Esther Marie Hatton Foundation  
e3 Wealth  
Eastdil Secured, LLC  
Deane Eastwood  
Eckert Seamans Cherin & Mellott  
ECN Financial LLC  
Ed & H Pillsbury Foundation  
Ed Morse Automotive Group  
The Edgerley Family Foundation  
Gerald Eisenberg  
Trisha and Chuck Eican  
Element Financial Corporation  
Emerson Charitable Trust  
Enerplus  
The Enrichment Foundation  
Enterprise  
Enterprise Holdings  
Enterprise Rent-A-Car  
Epizyme  
ePtus Technology, inc.  
EQT  
Eric Scherbarth Leukemia Research Foundation  
The Escher Foundation  
ESPN908  
Amir Etezadi  
Evolution Fighting Championship LLC  
Expeditors  
Express Scripts, Inc.  
The Eye Center of Charleston  
Bryan Ezralow  
Marc Ezralow  
Fairmont San Jose  
The Fama Family Charitable Fund  
Fansler Foundation  
Faramarz Fardshisheh  
Federal Realty Investment Trust  
Edward Fein  
Gail Fernandez  
America Ferrera  
The Ferriday Fund Charitable Trust  
Fidelity Brokerage Services, LLC  
Dorothy Fields  
Findlay Automotive Group  
Constance Fischer  
James Fisher  
Annie Flagg  
Flamingo Charities, Inc.  
Florida Crystals Corporation  
FMC Corporation  
Ford UAW Parts Depots  
Fox Valley Hematology & Oncology  
Fragrance Resources  
Dianne and Richard Franco  
Connie Frankino  
Fraunshun Hospitality Group of TN, LLC  
Fred Smith Plumbing & Heating Co.  
Freeman Boatworks, LLC  
Freeport Commodities, LLC  
Freight & Salvage Coffeehouse  
Friedman Advisors, LLC  
Friends of Katelyn  
Frank Furia  
G3 Enterprises  
Gables Residential  
Galen College of Nursing  
Garber Automotive Group  
Carlos Garcia  
Israel Garcia  
Gardner Family Trust  
T.H. Garner  
Gary and Pennie Abramson Charitable Foundation  
The Gaughen Management Group  
Chris Gauthreau  
Gaylord Hotels  
Frank Geary  
Anonymous  
Gene Foundation  
Genpact  
The George & Lena Valente Foundation  
George and Mary Josephine Hamman Foundation  
The George F. & Myra Shaskan Foundation, Inc.  
George L. Shields Foundation, Inc.  
The Gerald and Paula McNichols Family Foundation  
Gila River Casinos  
Ann and Peter Gilbert  
Global Payments, Inc.  
Global Traveler  
David Gochman  
Jason Goldberg  
Goldberg Charitable Trust  
Lee Goodwin and Linda Schwartzstein  
Tammy Gorham  
Bob Graham  
Grant Thornton LLP  
Greenberg Traurig  
Grip It & Rip It  
Bosa Grubich  
Anthony Guadagnino  
Janet and David Gualdoni  
Gulf Coast Bank & Trust Co.  
Jeff Gusinow  
H. Lee Moffitt Cancer Center & Research Institute  
HAC, Inc.  
Hadden Landscape, Inc.  
The Laverna Hahn Charitable Trust  
The Hallem Family  
Corb Hankey  
HARD Summer / Live Nation, Inc.  
Harkin Builders, Inc.  
Harlan Community High School  
Janet and John Harper  
Daniel Harrington  
Charles Harthan  
Clyde V. Hartline Jr.  
Donna Hartman  
The Harvey E. Najim Family Foundation  
Harv’s Car Wash 1901, LLC  
Allan Hawkins  
HCA West Florida  
Healthcare IT Leaders  
Heartland Express Inc.  
Healthcare Management Administrators  
HEB Grocery Company  
Heidrick & Struggles, Inc.  
The Helis Foundation  
Henkel’s & McCoy Inc.  
Henry Schein Cares  
Hewlett Packard Enterprise  
Hilltop Center, LLC  
Sam Hirbod  
HITT Contracting, Inc.  
The Hitz Foundation  
HM Life Insurance Company  
Hogan Lovells US, LLP  
Holistic Financial Partners  
Hope 4 Adam  
Liz Hoster  
Hot Ticket Racing  
Houston Methodist The Woodlands Hospital  
Howard Burris Family Gift Fund  
Howard Hannah Real Estate Services  
Eric Hoxsie  
The Hughes Family  
Richard Huxtable  
IBERIABANK  
ICE Mobility  
ImmunoGen  
Independent Health  
Indepth Gives Back  
Infinity Pharmaceuticals  
InfraSource, LLC  
Insulators International Health Hazard Fund  
Intouch Solutions  
IPA Foundation  
Iroquois Middle School  
The Irwin and Ginny Edlavitch Foundation  
The Isaacson iRV Trust  
ISN  
Ivie & Associates  
J.P. Morgan  
Jack Henry & Associates  
Jack Link’s  
2017 ACKNOWLEDGEMENTS
Jane and David Jackson
Jackson EMC
Luke Jaindl
Jaindl Beverage Co
Jaindl Farms, LLC
The James Cancer Hospital & Solove Research Institute
The James H. Reid, Jr. Family
James River Equipment
James T Ueltschi Foundation
Jan3150J LLC
Jacqueline Jankowski
Janus Henderson Foundation
Brian Jaramillo
The JBG Companies
JE Dunn Construction
Jewish Federation of Cleveland
John Edward Fowler Memorial Foundation
The John G. Rangos, Sr. Charitable Foundation
The John Newell Wade Foundation
John Wall Family Foundation
Diana and Murray Johnson
Judith and Jack Johnson
Louise Johnson
Edward Jones
Jones Day
Jones Lang LaSalle
Karen and Kent Jordan
George Joseph
Aaron Joyce
June & Cecil McDole Charitable Fund
K Machine Industrial Services
Kaiser Permanente
The Kaktal Family
Kansas Ready Mix, LLC
Kappa Sigma Theta-Delta
Kathryn Dent and John L. Tillman Charitable Fund
Kayleen Larson Legacy Foundation
KBS Trucking
KCE Structural Engineers
Mary Beth and Christopher Kearns
Thomas Kelley
Keiser
Keith Busse Enterprises
Kennedy Lane, LLC
Diane and Bill Kenny
KentuckyOne Health
KeyBanc Capital Markets
KeyBank National Association
Kiddar Group Holdings, Inc.
Kiro Roy Realty, LP
The Kirlin Group
Stuart Kirsch
John Kisthardt
Chuck Kiven
KLA Laboratories, Inc.
Chris Kolb
Koons Arlington Toyota
Joseph Kopser
Geraldine and Charles F. Kriser
Lisa and Steven Kristel
Shannon Krogh
K-VAC Environmental Services, Inc.
Luz Kynci
David Labuda
Stacy Lachapelle
Ladish Co. Foundation
Eddie Laflerty
The Laffey McHugh Foundation
Lake Family Foundation
Lake Norman Chrysler Dodge Jeep
Ram
Lalezarian Properties
Kelley and Jay Lamy
Land Rover
Landmark Construction
Tracy and Ben Lange
Langford Electric, Inc.
Lisa Lawin
Allison Lee
Left Hand Brewing Company
Leo Seal Family Foundation
Leon S. Peters Foundation
Ted Leonsis
Lewis Wagner, LLP
Jason Leyva
Life Science Tech, LLC
LifePoint Health
Lightning Foundation, Inc.
Linn Ligon
Lillie Young & Associates, LLC
Mike Linares
Connie Lindsey
Lion Ape ral
James Lites
Live Nation Worldwide, Inc. - TSO
Lizannei and Colbert Coldwell Foundation
Locke Lord, LLP
Lockton Companies
David Longo
Loretto Kane, John and Rosanne Strittmatter
Lori & Rick Rosmann Foundation
The Lotz Family Foundation
Low Book Sales
The Lowlands Group, LLC
Bruce Lowthers
The Ludwig Family Foundation, Inc.
Lustine Toyota Dodge
Allison and Howard Lutnick
M7 Aerospace
Mabee/Gumpert Philanthropic Fund
Mack Madness, Inc.
Robert Maher
Major Hyundai
Make Yourself Foundation
Chuck Malt
Manatt, Phelps & Phillips, LLP
Manpower International, Inc.
Maple Grove Elementary School
Mariner Holdings, LLC
Mark Miller Toyota
Lois Markovich
The Marksmen Company
Marquise Auction
Marsh Risk & Insurance Services
John Marten
Lucy Martin
Martin-O’Neil Cancer Center
Marty’s, Inc.
Mary lou’s Coffee
Mashkin Family Foundation
Massachusetts General Hospital
Kim and Matt Mausser
Maverick Capital Foundation
Jon Maxson
Frederic Mayerson
Mayo Clinic Cancer Center
Mayo Foundation for Medical Education and Research
Mayo Performing Arts Center
MB Financial Bank
Thomas McCarthy
McCownGordon Construction
Alta and Henry McCr a y
Laura and Paul McDaniel
McDermott Will & Emery
Erin and Sean McGould
The MCJ Amelior Foundation
Kathy and John McKinley
Stephanie and Edward McLaughlin
Matthew McManus
Scott McManus
Michele and Scott McMullin
Jennifer and Robert McNeil
William McNiff
MD Anderson Cancer Center
Mead Land Services
Medidata
Meg and Bennett Goodman Family Foundation
Megan’s Wings, Inc.
Danielle Meier
Joseph Meisner
Otilia Melwani
Members 1st F.C.U.
Memorial Health University Medical Center
Merchandise Pickup Service, Inc.
Meritor, Inc.
Caren and Phillip Merrick
Cayre and Alexis Michas
Microsemi Corporation
Miles & Stockbridge, PC
Mark Mills
Miller Paint Company
Eric Miller, MD
Nancy and Patrick Minan
Rusty and Barry Minkoff
Mitsubishi Hitachi Power Systems
Mizuho Americas
Monta Vista High School
Frank Moore
Donald Moreau
Morgan Franklin Consulting, LLC
Morgan Stanley
Morgan Stanley Foundation
Sasha Montz
Morris & Templeton Insurance
Marcie Morrison
Traci and Bill Morrow
Brint Morrow
Alicia Moya
Elizabeth M. Mungo
John Murphy
Murray & Guarri Trial Attorneys
Names Family Foundation
Leslie and Larry Nance
NASCAR Foundation
National Philanthropic Trust
National Rural Utilities Cooperative Finance Corporation
Nationwide Vision Center PC
Nature Nate’s - The Honey Rock Fund
Nature Nate’s - The Honey Rock Fund
Nature’s Variety
John Nauseef
Nebraska Medicine
Nestle Purina PetCare Company
NetApp
The Netter Foundation
New Car Dealers Association
Newmark Grubb Knight Frank
The Newsletter Pro
NextEra Energy, Inc.
The Niello Company
Nimble Storage
NOCO
Guy Nohra
Georgia North
North American Development Group
Northwell Health
The Northwest Company, LLC
Northwestern Mutual Foundation (WI)
Norton Cancer Institute
Norton Rose Fulbright US, LLP
Nova Restoration
NPL Construction Company
NWN Corporation
Morgan O’Brien
OHC
Richard Ojeda
Olafson Foundation
Chad O’Leary
The Omer Foundation
Wendy and Mike O’Neil
Nita and Michael Onustock
Ostrow Associates
Oxford Development
Pacific Coast Companies, Inc.
Pacific Service Credit Union
Mr. and Mrs. James F. Palmer
Palo Alto Networks Foundation
PAR Electrical Contractors, Inc.
Lynne Parshall
Joan Parsons
Mary Parsons
PathGroup
Patrick & Linda Foy Family Foundation
Patrick A. Bianchi Revocable Trust
Larry Patterson
Paul and Sandy Edgerley Trust Fund
Fidelity
The Paul and Sharon Dillon Family Fund
The Paul B. Greetin and Beryl S. Greetin Foundation, Inc.
The Paul E. Singer Foundation
Gina and Michael Pavelec
Pegasus Builders, Inc.
Anthony Pellegrino
Penn Color
Penn Medicine, Abramson Cancer Center
Penn Station East Coast Subs
Penn Waste, Inc.
Pennant Foods Corp DBA Wendy’s
Timothy Penney
PEP Promotions
Pepco Holdings, Inc.
Pepsi
Performance Honda Automotive Network
Whitney and Scott Perkins
Ernest Pestana
Pet Pugh Family Fund
Donita and Sheldon Petersen
PEW Charitable Trust
PGA TOUR Superstore
The Philadelphia Foundation
Tom Philbrick
Philly Open for LLS
Phoenix Suns Charities, Inc.
Pi Kappa Alpha Fraternity
Melissa and Mark Pietramale
Pietro’s Restaurant Group
James R. Pignataro
Pilot Travel Centers, LLC
Pineapple Classic Foundation
Pitt Ohio
Placer SPCA
PMG – Property Markets Group
PNC Bank
PNC Financial Services Group
PNC Real Estate
Polen Capital
Polo Ralph Lauren Foundation
Ports America
The Power Of Bowser
PPG Industries
Monika and John Preston
Priority Physicians
Private Advisor Group
ProCon, Inc.
PSEG Foundation
Public Service Enterprise Group Incorporated
The Pumping Station, Inc.
QiBQ, Inc.
Quality King Distributors
Quest Diagnostics
Kathleen and Edward Quinn
Mona and Peter Quinn
LaRee and Roger Quy
Rabobank International
Radiology Alliance, PC
Thomas Raffa
Rambus
The Randy and Deborah Daniel Family Charitable Foundation
Barbara Rapaport
Raymond James Financial
RCCA MSO, LLC
Real Estate One Foundation
RED Capital Group
Reece Holbrook Win Anyway Foundation, Inc.
Lisa and Bob Reeves
Mark Regante
Regeneron Pharmaceuticals, Inc
Reilly Foods Company
Angela and Michael Remen
David Rendina
Marjorie Rendina
Tricia and Richard Rendina
Rendimento Healthcare Real Estate
James Resnick
Resolution Run to Kick Cancer, Inc.
Chad Reynolds
The Rhoda and David Chase Family Foundation, Inc.
Richard & Terez Abatecola Foundation
The Richard and Charlotte Orear Charitable Foundation
Richard M. Schulze Family Foundation
Nina Richardson
Rick Hendrick Chevrolet
Ride Event
Linda and Paul Reid
Rifenburg Construction
Riot Games
RNDC South Carolina, LLC
RoadID
The Robert and Tina Gierkink Philanthropy Fund
Robert I. Goldman Foundation
The Robert Sprague Foundation
Ruth Robinson
Rock Spring Contracting, LLC
Rockefeller Group
Roderick S, Flossie R, & Helen M Galloway Foundation, Inc.
Lynn and Peter Rogers
Thomas Rogers
The Rogers Family Foundation
Annie Rose
Robert Rosen
Karen and Ernie Rosenberg
Lee Rosenthal
Roslyn Savings Bank
Ross Auerbach
Royals Charities, Inc.
RPM Pizza (Dominos Pizza)
Run This Town 5K
Ruoff Home Mortgage
Chris Russell
The Rutter Foundation
Rutti & Sons Construction
Jeffrey Sachs
The Safeway Foundation
Saint Benedict of New Jersey
Lauren and John Salata
HarveySaltzman
Sam I Am Foundation
Sam J. Frankino Foundation
Sam Swope Family Foundation, Inc.
Samuel C. Cantor Charitable Trust
Samuel P. Mandell Foundation
San Diego Sign Company
Sanofi Genzyme
SAPNS2
John Saunders
Rick Schaden
Schantz Orchards, LLC
Lisa Scheer and Ed Cone
Scheid Family Wines
Jeff Schoepfel
Schorr-Lieberman Family Foundation
Marlynn and William Scully
Seaboard Corporation
Seacap
Seattle Cancer Care Alliance
Seattle Genetics
Mark Seltzer
Sempra Employee Giving Network
Sessions, Nathan, Fishman & Israel
Shelley Shackelford
The Earl and Brenda Shapiro Foundation
Dave and Sally Shepherd
Sherwood Forest, SC
Shutterly
Linda and Bart Sichel
The Sidney, Milton and Leoma Simon Foundation
Signature Premier Properties
Silver State Schools Credit Union
Mr. and Mrs. Gregory Silvers
Lauren Simmons
Ira Simon
Gilbert Simonetti
Kathy and Jim Simpson
Sinkula Investments, Ltd.
Steman Kids
Skoda Contracting
SL Green
The Sleep Family
Alisa and Sean Slovenski
Douglas Smith
Jill Smith
Kristie Smith
Maria Smith
Michael Smith
Sue and Mike Smith
William Smith
Patricia Snyder
So Long to Leukemia
Jerome Solove
Southeast Nebraska Cancer Center
William Speakman
Spectrum Pharmaceuticals
Carol and Mark Spisak
Christina and H. Mark Sponseller
St. David's HealthCare
St. Mary's Indian Orthodox Church of Rockland
St. Thomas Orthodox Church of India, Houston
Gretnen Stangier
Star Anesthesia, ©
Patrick Starley
Barb and Tom Stayton
SteelFab, Inc. — South Carolina
David P. Steiner
Sterne, Kessler, Goldstein & Fox
Kay and Davis Stewart
John Stilley
Trevor Stokes
The Stout Family
Strikes Against Cancer
Sub Pop Records
Catherine Sullivan
Deborah Sullivan
Pam and Patrick Sullivan
Peace Sullivan
Suntrust Bank
Suntrust Foundation
Swedish Medical Center
Swing Fore the Cure
Jo Ann Swiontak
Jessica Symens
TAS Foundation
Ann Taylor
TCC
Tee Off Against Corporation
Temple Hoyne Buell Foundation
Tender Years, Inc. Child Development Centers
Teneo Strategy
Tennessee Oncology
Lee Tepper and Dorine Real
Terakeet, LLC
Texas Air Systems, LLC
Texas Instruments, Inc.
Judy and Michael H. Thomas
Thomas and Agnes Carvel Foundation
Sarah Thompson
Susan and John Thompson
Thompson & Knight, LLP.
Thompson, Habib & Denison, Inc.
Tilden-Coil Cares, Inc.
Tim and Sarah Jur Foundation
Tishman Speyer Properties, LP
Tito’s Handmade Vodka
Tom & Virginia Jernaro Family Foundation, Inc.
Tom Donaldson, Papa John’s Foundation, Inc.
The Tony and Cori Bates Family Foundation
Tooley Oil Company
Total Wine and More
Dan Towriss
Toyota of Gladstone
Transwestern
TriAgile
Linda and Bob Triplett
Paul Trotter and Elizabeth Neuman
Truth North
Trust Company of the South
The Tsern Foundation
Kevin and Kristin Tu
Turner Construction Company
Cal Turner, Jr.
TurningPoint Global Solutions, LLC
U.S. Chamber Of Commerce
U.S. Coffee RE Doug Shindler
UBS Financial Services, Inc.
UCHealth
Uhlig, LLC
Unanet
Union Bank
Union Bank & Trust Co
United Networks of America
United Way of San Antonio and Bexar County
UnitedHealthCare Mid-Atlantic University Hospitals
The University of Kansas Cancer Center
Unvision Management Company
Urban Concrete Contractors, Ltd.
US Bank
US Bank National Association
US Mortgages
Beth and Natan Vaisman
The Van Metre Family Foundation, Inc.
Vanguard Charitable Endowment
Vantage Oncology, Inc.
Mari Vasan
VCU Health System
The Vecellio Family Foundation, Inc.
Viacom
Lois Vick
Katy Vickery
The Victor E. and Caroline E. Schutte Foundation - 1959
Vidaris/LPI
Vodafone US, Inc.
Volkert, Inc.
VWR Charitable Foundation
The W. O’Neil Foundation, Inc.
Walter Wacker
Waffle House Foundation, Inc
Wampus Pere Wakah
Waverly University School of Medicine
Waste Technology Services, Inc.
Wawanesa Insurance
Waxman Strategies
WCAV TV
Visse Wedell
Wedell Foundation (Marsha Wedell)
Wegman, Hessler & Vanderburg
The Weiler Foundation
David Weinstein
Shari and Marc Weissbach
WellHealth Quality Care
Marvin Wenger
Dayton Werner
Westchester Triathlon Committee
Western Refining
WGNV radio
Charles Wharton
Whelan Securities
WHM, LLC
Kelly Wiechman
Missy and Drew Wiedhorn
Colleen and William Wildner
The William G. Pomeroy Foundation
Cane Williams
Tom Williams
Williams & Connolly, LLP
Wills Towers Watson
Patricia Wilson
Judie and James Wilson
Kendrick Wilson
The Winkler Family Foundation
Winnisboro Petroleum Company
Wisnoski Family Fund in memory of Jackie
Withum, Smith & Brown
WVBF- TV, Channel 4/CW23
Woodforest National Bank
The Woodlands Development Company
World Bank Community Connection Fund
WRGB CB56 TV
Tonia Wurzelbacher
yb-squared
Caroline Young
Young Hearts, Inc.
Young Texans Against Cancer
Adelaide Zacriske
Cathy and Scott Zeilinger
The Zenith Insurance Company
Zotec Partners, LLC
Joseph Zvesper
Anonymous (27)
Top Campaign Fundraisers

ADF Companies - Pizza Hut
Aetna
All in for LLS
Sandy Allen-Bard
Nicole Ameduri Gonul
Amgen
Barbara Anderson
Jenny Anderson
Andrew Dale & Team "No One Fights Alone"
Andrew Foley's Campaign Team
C.E. Andrews
Vicky Andritsch
Ann Street Elementary School
Robert Annable
Michael Applebaum
Rob Armstrong
At Home
August Robertson & Team Gus
Avella Specialty Pharmacy
Mae Babington
John Bacon
Bank of America
Bank of America Merrill Lynch
Banner MD Anderson
Barclays
Michae Barry
Alexander Basse
BD
BDO
Amy Beachy
Beat It
Hallee Becher
Ella Behnke
Stacy Bennett, MD
Josh Bernstein
Meg & Luke Bernstein
Wayne Berson
The Beta Chapter of Sigma Alpha Epsilon
Barclay Bishop
Blackstone
Rich Blaklick
Sophie Blasberg
BloodType: Brooklyn
Brad Blumenfeld
BMC
Leslie Bohl
Box Out Cancer
Chase Bradley
Denise Bradley
R. Michael Brannock, Jr.
Dow Brantley
David Breen
Amanda Brewer
Angie Brinkmeyer
Katie Briscoe
Bristol-Myers Squibb
Brittany Rouse & Team Freedom
John Bunce
Adam Burck
June Burke
Burlington
Jayme Butcher
Amada Butler-Eisenfeld
Jon Butts
Caitlin Fitzgerald & Cross My Heart and Hope to Live
Dianne Callahan
Bonnie Campagnuolo
Cancer Crusaders
Robert “Spider” Cantley
David A. Caplan
Stephanie Carroll
Bill Carteaux
Carter’s, Inc.
Celgene Corporation
Keegan Chapman
Charles Esten’s Team Addie
Nadia Christensen
Shar Christopher
Spencer Coker
Melissa Coligan
Colton’s Army
Tim Connor
Robert Cornett
Ian Coyle
Court Creeden
Matt Cromar
Crushin' Orange
Ashley Curry
Jennifer Curry
Dan Cote & Team Pure4The Cure
Jana Davenport
J. Greg De Felice
Jason Dehaemers
Deltotte
Larissa DeMarco
Joseph DeSavia
Tom DeTulleo
Emily Dickinson
Robert Dickinson
Dave DiLuigi
Discount Tire
Chris Donahoo
Mary Jo Doughtery
Dow Brantley’s Campaign Team
Matt Doyle
Jonathan Duerr
Emily Dumler
Amy Eberhardt
Molly Egloff
Stephanie & Andy Eichberg
Sally Ekus
Moustafa El Hariry
Elit Systems of America
Meghan Eiler
EY
Katie Falk
Kevin Fay
Nicole Fink
FIS
Kyle B. Fisher
Brooke Fitzgerald
Five & Alive
Rebecca Foerster
Andrew Foley
Clayton Forman
Patrick Foy, M.D.
Kyle Fritsch
Erik Fromm
Mike Gebhardt
Hillary Gelfman
Genentech/Biogen Idec
Neda Ghahremani
Taki Gikakis
Gila River Casinos
Scott Gildea
Gilead
Sue Gilles
Global Franchise Group
Go Team Trent
Ali Goethel
John D. Goetz
Goldman Sachs
Tricia Gonyo
Jamie Graham
Michael Graham
Eric Green
Greene Team
Emery Greenwood
Sophia Gregory
Anthony Guadagnino
Brianna Haag
Virginia Hall
Timi Hallem
Tammi K. Hanak
Martha Handrich
Joan Haratani
Michelle Harding Lorber
Adam Harris
Jessica Harrison
Megan Hart
Kathy Hawkins
Henry Jacobson & Team Suck-It-Cancer
Heroes for Hazel
Paul Hickman
Tim Hodges
Zoe Holland
Tracy Howard
Katherine Hurd
Thayer Hutcheson
In Memory of Rick Horstman
Jaime Orozco & Team Mickey
Luke Jaindl
Jakob Duchesneau & Team Brick Breakers
Maddie Jebavy
Jerry Maahs Memorial Golf Outing
Jessica Johnson
Jonathan Fields & Team Hope
Jonathan Gabay & The A-Team
Jorge Rico and Team Jorge Strong
Just Cure It
Just Cure the Damn Thing
Michelle Kadiacek
Betsy Katten
Amanda Kay
Mallory Keating
Kelly Delaney, Ellie Strockis & Team Kelly’s Cancer Killers
Curt Kersey
Kiven, Kotler, Lieberman, Fox, Joffe, Goldschmidt & Kepes
Mason Klein
John Klein
Jared Knertel
Koppers
Chris Kostanecki
Robert Kottler
KPMG
J.P. Kramer
Annabel Krebs
Anthony Lallis
Molly Levine
Alyssa Lewandowski
Jason Liljenquist
Paul Lilles
Jason Llewellyn
Al Lord
Amanda Lucero
Tood MacKay
Scott Madaus
Karen Maginn
Lois Markovich
Katie Martin
Valerie Fiordilino Maslow
Kelly Masterson
Sher Mathew
Matt Smith & Team Why We Fight
Nicole Matthews
Tim McBride
Meghan McCann
Chris & Gary McGraw
Amanda McHenry
Mark McIntosh
Julie McKenzie
Anne McLaughlin and Team Grant Strong
Mark McLaughlin
Matt McNally
Ryan Melendez
Nadine Mentor
Michael Milberg & Team 828
Shelley Miller
Mindy Miller Hill
Beatrice Miranda
Jessie Miranda
Missy’s Mojo
Rafael Mizrachi
Stephanie Montz
MWOY Leadership Team Circle of Hope
Shahn Naghavi
UCLA Health
Sarah Cannon/HealthONE
Virginia Shantz
Bill Shaw
Shen Stewart / Defy the Verdict
Ariel Shiffer
Rebecca Shope
Tommy Shriver
Vershalee Shukla, M.D.
Morgan Signora
Alexandra Singer
Kathy M. Silencak
Kirsten Smith, M.D.
Ryan Snow
SoCalGas
Society Ties
Teresa Spittle
Kirk Sran
Shaylor Steele
Donald Steiner
Lillyana Stephanakis
Stater Bros. Charities
Stratford School - Fremont Campus
Julia Strittmatter
Steven Sullivan
Andrea Zolom Satter and Team Live Love
Sydney Clark, Jomsky & Team Panther Paws for a Cause
Takeda Oncology
Team b.strong
Team Believe
Team Blumenfeld & Waterman
Team Bright Side
Team CUREageous
Team Deere in Memory of Bryant Ante
Team Driving Miss Carmen
Team Farewell No More
Team Generac
Team Haley in Honor of Haley Marston
Team It ALL Matters
Team Jamie
Team Javan
Team Michael
Team OneinaPREMILlion
Team Ride Brook
Team Rise For a Cure
Team RonStrong
Team Shaylor Shukla
Team SHINE

2017 ACKNOWLEDGEMENTS
Legacy Circle

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year.

Catherine Hunt Alspach
Henry Acad*
Joan Applebome (in memory of Jeffrey Paul Baker)
Stephanie Arcei*
Edward Mitchell Badgett*
Ralph Barone*
Patricia Bender (in memory of Joseph A. Dubuc)
Joyce Benson*
Robert Berrey*
Patrick Bianchi*
Mary L. Blair
Tom Boylan
Keith Brantley*
Frank and Sue Brooks*
Mary Alice Brown*  

Research Portfolios

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. The list below includes donors that generously invested in a specific LLS research portfolio during this fiscal year.

Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Abbeville Family Partnership, Charles Godchaux - Charles Foundation, Becky Godchaux, Thomas McCarthy, and Leslie and Larry Nance.

Chronic Myelogenous Leukemia Research Portfolio is funded in part by the Carlson Family Foundation Inc., John Marten, Randy and Deborah Daniel.

Doris Koch*
Edward Kramer (in memory of Connie Kramer)
Eduardo Maciel*  

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by the Carlson Family Foundation Inc., John Marten, Randy and Deborah Daniel.

Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by the Carlson Family Foundation Inc., John Marten, Randy and Deborah Daniel.

Pediatric and Young Adult Blood Cancer Research Portfolio is funded in part by American Construction Company, EFESTÉ Franklin American Mortgage Company, Megan’s Wing Foundation, The Rhoda and David Chase Family Foundation, Inc., Team Bright Side, the Thomas and Agnes Carvel Foundation, and the Wawa Foundation.

Lymphoma Diagnostics Program is funded in part by Chiyoko Furukawa.

Mission Portfolio is funded in part by Ping Y. Tai Foundation, Inc.

Patient Services Program is funded in part by CareFirst BlueCross BlueShield and the Gerald and Paula McNichols Family Foundation.
Endowment Funds

The Bill Beattie Memorial Endowment Fund (Alberta)
Mary & Robert Bronstein Memorial Fund
The Virginia Major Brooks Memorial Endowment Fund
de Villiers Endowment Fund
Thomas M. Ford Memorial Fund
GlaxoSmithKline Foundation - Gertrude B. Elion Endowment Fund
GlaxoSmithKline, Inc. Research Fund
Jim Jacobs Leukemia Research Fund

The Rachel Kudish Fund
Jane Eloisa/Charlotte Meyers Endowment Fund
The Rae Endowment Fund (Ontario)
Vrushali Ranadive Fellowship Fund
Reich Endowment Fund
The United Food and Commercial Workers (Canada) Endowment Fund
Leadership

National Board
Volunteers serve on our National Board of Directors providing leadership and governance to help find blood cancer cures.

Chairman of the Board
Peter Brock
Brock Development
Palm Beach Gardens, FL

Vice Chair
Jorge Benitez
Fort Lauderdale, FL

Secretary/Treasurer
Ralph E. Lawson, FHFMA, CPA
Baptist Health South Florida
Coral Gables, FL

At Large
Raanan Horowitz
Elbit Systems of America, LLC
Fort Worth, TX

Board of Directors
James Beck
Hefren-Tillotson, Inc.
Butler, PA

William G. Behnke
The Behnke Group
San Antonio, TX

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Renzo Canetta, MD
Madison, CT

Scott A. Carroll, JD
Jackson Lewis
Cincinnati, OH

Elizabeth J. (Betsy) Clark, PhD.
Saugerties, NY

William S. Dalton, MD, PhD
M2Gen
Tampa, FL

Bernard H. Garil
Delray Beach, FL

Francie Heller
Heller Advisory
New York, NY

Richard M. Jeanneret
Ernst & Young LLP
New York, NY

Joseph B. Kelley
Lilly USA, LLC
Washington, DC

Michelle LeBeau, PhD
University of Chicago Comprehensive Cancer Center
Chicago, IL

Connie L. Lindsey
Northern Trust
Chicago, IL

Kathleen Meriwether
Ernst & Young, LLP
Philadelphia, PA

Ted Moroz
The Beer Store
Ontario, Canada

Donald Proctor
Walnut Creek, CA

Steven T. Rosen, MD, FACP
City of Hope
Duarte, CA

Kenneth Schwartz
Ernst & Young, LLP
New York, NY

Bart Sichel
Burlington Stores
Florence Township, NJ

Frank O. Smith, III, MD
Medpace
Cincinnati, OH

Kathryn C. Vecellio
The Vecellio Group
Palm Beach, FL

Louise G. Warner
Chagrin Falls, OH

Keith S. White
ParkerWhite Brand Interactive
Cardiff by the Sea, CA

Executive Leadership

The Leukemia & Lymphoma Society

Louis J. DeGennaro, PhD
President & Chief Executive Officer

Andrew S. Coccari
Executive Vice President
Chief Product Officer

The Leukemia & Lymphoma Society of Canada

Shelagh Tippet-Fagyas
President
Canadian Operations

Offices

United States:
https://www.lls.org/
chapter-selection-page

Canada:
http://www.llscanada.org/
chapter-selection-page
OUR MISSION